amlodipine and Diabetes Mellitus, Type 2 studies

Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.

Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Research Excerpts

Excerpt	Relevance	Reference
"Type 2 diabetic subjects with hypertension 30 to 80 years of age who were not taking antihypertensive drugs were randomized into either valsartan (n = 33) or amlodipine (n = 35) groups and treated for 24 weeks."	9.24	Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study. ( Ahn, YB; Choi, SH; Han, SJ; Jang, HC; Kim, DJ; Kim, HJ; Kim, HY; Kim, NH; Kim, SH; Kim, TH; Kim, YH; Ko, SH; Lee, KW; Lim, S; Seo, JA; Shin, DH, 2017)
"To examine the antihypertensive efficacy and safety of indapamide sustained-release (SR)/amlodipine compared with enalapril/amlodipine in patients 65 years and older with uncontrolled blood pressure (BP) on monotherapy, a post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria) was conducted."	9.24	Blood pressure-lowering efficacy of indapamide SR/amlodipine combination in older patients with hypertension: A post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria). ( Boully, C; Caillard, L; Chaussade, E; Hanon, O; Hernandorena, I, 2017)
"Hypertensive diabetic patients with microalbuminuria were included in this retrospective, post-hoc analysis of the Natrilix SR Versus Enalapril Study in Hypertensive Type 2 Diabetics With MicrOalbuminuRia (NESTOR) trial if they were uncontrolled on monotherapy (indapamide slow release (SR) 1."	9.20	Treatment of Hypertensive Patients With Diabetes and Microalbuminuria With Combination Indapamide SR/Amlodipine: Retrospective Analysis of NESTOR. ( Boully, C; Caillard, L; Chaussade, E; Cochiello, S; Hanon, O; Labourée, F, 2015)
" The efficacy and safety of 20-week treatment with an amlodipine (AML)/olmesartan medoxomil (OM)±hydrochlorothiazide (HCTZ) algorithm were assessed in patients with hypertension and type 2 diabetes mellitus (T2DM) who were uncontrolled by antihypertensive monotherapy."	9.17	Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). ( Maa, JF; Nesbitt, SD; Shojaee, A; Weir, MR, 2013)
" Hypertensive patients with type 2 diabetes mellitus and albuminuria (≥30 mg g(-1) creatinine) were enroled in the study, and were either started on or switched to candesartan (8 mg per day) monotherapy."	9.16	Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria. ( Dohi, Y; Ichikawa, T; Ito, M; Kato, T; Kimura, G; Kojima, M; Komada, T; Machida, H; Miyazaki, T; Nakatani, K; Ninomiya, T; Okura, T; Sugiyama, M; Watanabe, Y, 2012)
"The objective of this study was to compare valsartan or ramipril addition to amlodipine + hydrochlorothiazide (HCTZ) on blood pressure (BP) and left ventricular hypertrophy (LVH) in hypertensive diabetic patients with LVH."	9.16	Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Preti, P; Zoppi, A, 2012)
"We examined blood pressure reduction and metabolic alterations after amlodipine/benazepril and valsartan/hydrochlorothiazide treatment in patients with type 2 diabetes mellitus and hypertension and microalbuminuria."	9.16	Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando ( Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012)
"We studied the effects of treatment with olmesartan/amlodipine and olmesartan/hydrochlorothiazide on inflammatory and metabolic parameters (including new-onset diabetes as a secondary endpoint) in non-diabetic hypertensive patients with metabolic syndrome (MetS)."	9.15	Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. ( Comi-Diaz, C; Martinez-Martin, FJ; Pedrianes-Martin, P; Peiro-Martinez, I; Rodriguez-Rosas, H; Soriano-Perera, P, 2011)
"The safety and efficacy of an amlodipine/olmesartan medoxomil (OM)-based titration regimen was assessed in patients with type 2 diabetes mellitus and hypertension."	9.15	Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. ( Littlejohn, T; Neutel, JM; Qian, C; Ram, CV; Sachson, R; Shojaee, A; Stoakes, KA, 2011)
"Forty type 2 diabetic patients with hypertension and nephropathy receiving angiotensin receptor II blockers were enrolled and randomly divided into two groups: the efonidipine group was administered efonidipine hydrochloride ethanolate 40 mg/day and the amlodipine group was admin-istered amlodipine besilate 5 mg/day for 12 months."	9.14	Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohhira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Yamaguchi, T, 2009)
"The ADHT (Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial) evaluated the efficacy and safety of adding amlodipine to the treatment regimen of patients with hypertension and diabetes who were already receiving either quinapril or losartan as monotherapy."	9.13	Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial. ( Gregg, AM; Kloner, RA; Neutel, J; Roth, EM; Schwartz, B; Shi, H; Thakker, KM; Weinberger, MH; Weiss, R, 2008)
"The aim of this study was to compare the efficacy and safety of adding manidipine 20 mg versus amlodipine 10 mg to the treatment of diabetic patients with uncontrolled hypertension and microalbuminuria despite full-dose treatment with a renin-angiotensin system blocker for at least 6 months."	9.13	Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. ( Martinez-Martin, FJ; Saiz-Satjes, M, 2008)
"The aim of this study was to compare the effect of valsartan/amlodipine and atenolol/amlodipine combination in preventing the recurrence of atrial fibrillation (AF) in hypertensive diabetic patients with a history of recent paroxysmal atrial fibrillation."	9.13	Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008)
"In addition to reducing urinary protein excretion, losartan at 100 mg daily increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetic nephropathy."	9.12	Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. ( Jin, HM; Pan, Y, 2007)
"Aim of this study was to evaluate the effect of the telmisartan-amlodipine combination at different doses on urinary albumin excretion rate (UAER) in hypertensive diabetic patients with microalbuminuria."	9.12	Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. ( Derosa, G; Destro, M; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007)
"Three hundred thirty-two patients with type 2 diabetes and microalbuminuria, with or without hypertension, were randomly assigned to 80 mg/d valsartan or 5 mg/d amlodipine for 24 weeks."	9.10	Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. ( Viberti, G; Wheeldon, NM, 2002)
"We selected 453 hypertensive patients with type 2 diabetes and microalbuminuria and randomized them to amlodipine (5 to 15 mg/day), fosinopril (10 to 30 mg/day), or amlodipine plus fosinopril (5/10 to 15/30 mg/day) for a 3-month titration period."	9.10	Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Marasi, G; Mugellini, A; Pasotti, C; Poletti, L; Preti, P; Rinaldi, A; Voglini, C; Zoppi, A, 2002)
"In this 1-year clinical study, we compared the efficacy and tolerability of amlodipine and nifedipine retard in 64 Chinese Type 2 diabetic patients with hypertension."	9.09	Blood pressure reduction and tolerability of amlodipine versus nifedipine retard in Chinese patients with type 2 diabetes mellitus and hypertension: a randomized 1-year clinical trial. ( Chan, CH; Chan, HC; Ko, GT, 2001)
" The primary aim of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) was to compare the effects of fosinopril and amlodipine on serum lipids and diabetes control in NIDDM patients with hypertension."	9.08	Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. ( Byington, RP; Di Mauro, P; Guarisco, R; Pahor, M; Strollo, F; Strollo, G; Tatti, P, 1998)
"Compared with amlodipine, fimasartan increased late-phase glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension."	7.88	Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine. ( Ahn, CH; Cho, YM; Jung, HS; Kim, S; Kwak, SH; Lee, SO; Lim, MH; Mari, A; Park, KS; Roh, E; Yang, YS, 2018)
"to assess in patients with arterial hypertension and type 2 diabetes the effect of perindopril / amlodipine fixed combination on arterial wall stiffness (AWF) and microcirculation, and relationship between AWF parameters and the state microcirculation."	7.88	[Influence of Therapy With Fixed Combination of Perindopril and Amlodipine on Parameters of Elasticity of Main Vessels and Microcirculation in Patients With Arterial Hypertension and Type 2 Diabetes Mellitus]. ( Statsenko, ME; Titarenko, MN; Turkina, SV, 2018)
" This subanalysis of the Clinical Utility of Caduet in Simultaneously Achieving Blood Pressure and Lipid End Points (CAPABLE) trial studied attainment of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) and the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) goals by 8 flexibly titrated doses (5/10-10/80 mg) of amlodipine/atorvastatin single pill in 494 African Americans with hypertension and dyslipidemia, according to the presence of diabetes +/- the metabolic syndrome."	7.75	Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus. ( Ferdinand, KC; Flack, JM; Jamieson, MJ; Kursun, A; Saunders, E; Shi, H; Victor, R; Watson, K, 2009)
"Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR."	6.74	Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009)
"Seventy type 2 diabetes mellitus patients with hypertension were enrolled and randomly divided into two groups."	6.74	Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohira, M; Oyama, T; Saiki, A; Shirai, K; Yamaguchi, T, 2009)
"To evaluate, in patients with type 2 diabetes and hypertension, the effects of 6 months treatment with canagliflozin, or perindopril, an angiotensin converting enzyme inhibitor, on central BP and carotid-femoral pulse wave velocity (cfPWV)."	5.51	Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril. ( Ramirez, AJ; Sanchez, MJ; Sanchez, RA, 2019)
"Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity."	5.36	Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010)
" A total of 121 participants with type 2 diabetes and uncontrolled essential hypertension, who were receiving medium doses of amlodipine (5 mg/day) and ARB, were enrolled."	5.30	Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study. ( Fukushima, M; Hoshino, F; Imaizumi, S; Kusumoto, T; Matsunaga, A; Miura, SI; Morito, N; Nagata, Y; Norimatsu, K; Ogawa, M; Sako, H; Saku, K; Shiga, Y; Shimono, D; Shirotani, T; Sugihara, H; Tanigawa, H; Uehara, Y; Yahiro, E, 2019)
"Type 2 diabetic subjects with hypertension 30 to 80 years of age who were not taking antihypertensive drugs were randomized into either valsartan (n = 33) or amlodipine (n = 35) groups and treated for 24 weeks."	5.24	Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study. ( Ahn, YB; Choi, SH; Han, SJ; Jang, HC; Kim, DJ; Kim, HJ; Kim, HY; Kim, NH; Kim, SH; Kim, TH; Kim, YH; Ko, SH; Lee, KW; Lim, S; Seo, JA; Shin, DH, 2017)
"To examine the antihypertensive efficacy and safety of indapamide sustained-release (SR)/amlodipine compared with enalapril/amlodipine in patients 65 years and older with uncontrolled blood pressure (BP) on monotherapy, a post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria) was conducted."	5.24	Blood pressure-lowering efficacy of indapamide SR/amlodipine combination in older patients with hypertension: A post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria). ( Boully, C; Caillard, L; Chaussade, E; Hanon, O; Hernandorena, I, 2017)
" A total of 74 patients with T2D and microalbuminuria treated with renin-angiotensin system (RAS) blockers were randomized to a cilnidipine 10 mg treatment (n=38) or amlodipine 5 mg treatment (n=36)."	5.24	Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial. ( Cha, BS; Chung, CH; Hwang, YC; Jang, HC; Lee, KW; Lee, MK; Min, KW; Yoon, KH, 2017)
"In AMANDHA trial, the addition of manidipine, but not amlodipine, in diabetic patients with uncontrolled hypertension, microalbuminuria and preserved renal function resulted in a large decrease of urinary albumin excretion (UAE) despite similar blood pressure (BP) reductions."	5.24	Factors associated with the reduction of albumin excretion in diabetic hypertensive patients: differential effect of manidipine versus amlodipine. ( Martinez-Martin, FJ; Roca-Cusachs, A; Saiz-Satjes, M, 2017)
"This post hoc analysis from the Sevikar Compared to the Combination of Perindopril Plus Amlodipine on Central Arterial Blood Pressure in Patients With Moderate-to-Severe Hypertension (SEVITENSION) study assessed the efficacy and tolerability of olmesartan (OLM) and amlodipine (AML) in reducing central systolic blood pressure (CSBP) compared with perindopril (PER) plus AML in hypertensive patients with type 2 diabetes."	5.22	Fixed-Combination Olmesartan/Amlodipine Was Superior to Perindopril + Amlodipine in Reducing Central Systolic Blood Pressure in Hypertensive Patients With Diabetes. ( Ruilope, LM, 2016)
"The combination olmesartan/amlodipine is safe, well tolerated, and as effective as the combination of perindopril/amlodipine in the control of essential hypertension in patients with diabetes mellitus."	5.22	Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes. ( Pichler, G; Redon, J, 2016)
"The aim of this study was to compare the effects of a dihidropiridin calcium channel blocker amlodipin and a non-dihidropiridin calcium channel blocker verapamil on nephropathy and serum pigment epithelium-derived factor (PEDF) levels of type 2 diabetic patients with hypertension."	5.20	The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus. ( Çelik, H; Korkmaz, H; Oğuz, E; Sabuncu, T; Tabur, S, 2015)
"Hypertensive diabetic patients with microalbuminuria were included in this retrospective, post-hoc analysis of the Natrilix SR Versus Enalapril Study in Hypertensive Type 2 Diabetics With MicrOalbuminuRia (NESTOR) trial if they were uncontrolled on monotherapy (indapamide slow release (SR) 1."	5.20	Treatment of Hypertensive Patients With Diabetes and Microalbuminuria With Combination Indapamide SR/Amlodipine: Retrospective Analysis of NESTOR. ( Boully, C; Caillard, L; Chaussade, E; Cochiello, S; Hanon, O; Labourée, F, 2015)
"213 patients with type 2 diabetes mellitus and hypertension were randomized to amlodipine 5 mg, or amlodipine 5 mg + ASA 100 mg for 3 months (Phase A); then, if adequate blood pressure control was reached patients terminated the study; otherwise, amlodipine was up-titrated to 10 mg/day for further 3 months and compared to amlodipine 10 mg + ASA 100 mg (Phase B)."	5.20	A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. ( D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM, 2015)
"Patients with diabetes and hypertension with office systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 80 mmHg had their antihypertensive medications replaced by amlodipine during 6 weeks."	5.20	Renin-Angiotensin System Blockade Associated with Statin Improves Endothelial Function in Diabetics. ( Bedirian, R; Gismondi, RA; Ladeira, MC; Neves, MF; Oigman, W; Pozzobon, CR, 2015)
"A total of 439 hypertensive patients with metabolic syndrome and/or diabetes mellitus were randomized to 2 groups: group 1--ramipril (ACE-I) or perindopril and group 2--losartan (ARB)."	5.19	Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the M E D I N A study). ( Soucek, M; Spinar, J; Vitovec, J, 2014)
"Patients with a previous diagnosis of hypertension and type 2 diabetes mellitus were randomly divided into 2 groups and evaluated after 6 weeks of treatment with amlodipine (5 mg/day) or losartan (100 mg/day)."	5.19	Functional vascular study in hypertensive subjects with type 2 diabetes using losartan or amlodipine. ( Bedirian, R; Gismondi, RA; Ladeira, MC; Neves, MF; Oigman, W; Pozzobon, CR, 2014)
"To evaluate the impact of 6-month antihypertensive therapy with the combined drug amlodipine + lisinopril (ekvator) on endothelial dysfunction (ED) and carbohydrate metabolic parameters in patients with hypertension and type 2 diabetes mellitus (DM)."	5.19	[Correction of endothelial dysfunction in hypertensive patients with type 2 diabetes mellitus during combined antihypertensive therapy]. ( Derevianchenko, MV; Statsenko, ME, 2014)
" Intact FGF-23, the eGFR, proteinuria and the endothelium-dependent flow-mediated (FMD) response to ischemia and other parameters were measured at baseline and after 12-weeks of treatment with ramipril (n = 68) or amlodipine (n = 32)."	5.19	Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy. ( Cetinkaya, H; Eyileten, T; Gok, M; Karaman, M; Kurt, YG; Mallamaci, F; Oguz, Y; Saglam, M; Sonmez, A; Unal, HU; Vural, A; Yilmaz, MI; Zoccali, C, 2014)
"To evaluate whether the direct renin inhibitor, aliskiren, has a more favorable effect compared to amlodipine on atherosclerotic biomarkers in patients with stable coronary artery disease and diabetes currently receiving standard secondary prevention therapy."	5.17	Effects of direct renin inhibition on atherosclerotic biomarkers in patients with stable coronary artery disease and type 2 diabetes mellitus. ( Abo-Salem, E; Doctolero, S; Irons, BK; Meyerrose, GE; Seifert, CF; Simoni, JS; Trujillo, A, 2013)
"In this prospective, multicenter, open-labeled, randomized trial, the antialbuminuric effects of cilnidipine and amlodipine were examined in renin-angiotensin system (RAS) inhibitor-treated patients with hypertension (blood pressure [BP]: 130-180/80-110 mmHg), type 2 diabetes, and microalbuminuria (urinary albumin to creatinine [Cr] ratio [UACR]: 30-300 mg/g)."	5.17	Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial. ( Ando, K; Fujita, T; Kosugi, S; Matsuoka, H; Nakao, K; Sato, T; Tanaka, S; Ueshima, K, 2013)
"To evaluate the impact of combination antihypertensive therapy with lisinopril + amlodipine (Ekvator) on endothelial dysfunction in patients with hypertension and concurrent type 2 diabetes mellitus (T2DM)."	5.17	[Endothelial dysfunction is a target for combination antihypertensive therapy in hypertensive patients with type 2 diabetes mellitus]. ( Bondarev, AM; Derevianchenko, MV; Ostrovskiĭ, OV; Shvets, MK; Statsenko, ME; Titarenko, MN, 2013)
"Hypertensive patients with type 2 diabetes mellitus and microalbuminuria under treatment with a combination of a standard dose of telmisartan (40 mg/day) and trichlormethiazide (1 mg/day) were randomly assigned to receive either an increased dose of telmisartan (80 mg/day) combined with trichlormethiazide [increased dose angiotensin receptor blocker (ARB) group, n = 20] or a combination consisting of telmisartan (40 mg/day), trichlormethiazide, and amlodipine (5 mg/day) (triple combination group, n = 20) for 6 months."	5.17	Titration of telmisartan, but not addition of amlodipine, reduces urine albumin in diabetic patients treated with telmisartan-diuretic. ( Dohi, Y; Kimura, G; Kojima, M; Ohashi, M, 2013)
" The efficacy and safety of 20-week treatment with an amlodipine (AML)/olmesartan medoxomil (OM)±hydrochlorothiazide (HCTZ) algorithm were assessed in patients with hypertension and type 2 diabetes mellitus (T2DM) who were uncontrolled by antihypertensive monotherapy."	5.17	Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). ( Maa, JF; Nesbitt, SD; Shojaee, A; Weir, MR, 2013)
" Hypertensive patients with type 2 diabetes mellitus and albuminuria (≥30 mg g(-1) creatinine) were enroled in the study, and were either started on or switched to candesartan (8 mg per day) monotherapy."	5.16	Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria. ( Dohi, Y; Ichikawa, T; Ito, M; Kato, T; Kimura, G; Kojima, M; Komada, T; Machida, H; Miyazaki, T; Nakatani, K; Ninomiya, T; Okura, T; Sugiyama, M; Watanabe, Y, 2012)
"To compare the effects of losartan and amlodipine on myocardial structure and function in hypertensive patients with Type 2 diabetes and left ventricular hypertrophy."	5.16	Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. ( Corradi, L; Derosa, G; Destro, M; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2012)
"A total of 170 outpatients aged 50-75 years with mild to moderate hypertension (SBP >130 and <180 mmHg and DBP >80 and <100 mmHg) and type 2 diabetes were randomly treated with aliskiren 300 mg or amlodipine 10 mg, both given once daily for 24 weeks, according to a prospective, open label, blinded-end point, parallel group design."	5.16	Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Monti, C; Mugellini, A; Zoppi, A, 2012)
"The aim of the study was to investigate whether the single-pill combination of telmisartan and amlodipine was superior to amlodipine alone as initial antihypertensive therapy in patients with diabetes and hypertension."	5.16	Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. ( Bakris, G; Kobe, M; Ley, L; Littlejohn, TW; Neutel, JM; Sharma, AM; Ting, N, 2012)
"The objective of this study was to compare valsartan or ramipril addition to amlodipine + hydrochlorothiazide (HCTZ) on blood pressure (BP) and left ventricular hypertrophy (LVH) in hypertensive diabetic patients with LVH."	5.16	Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Preti, P; Zoppi, A, 2012)
"We examined blood pressure reduction and metabolic alterations after amlodipine/benazepril and valsartan/hydrochlorothiazide treatment in patients with type 2 diabetes mellitus and hypertension and microalbuminuria."	5.16	Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando ( Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012)
"A total of 263 type 2 diabetes with hypertension refractory to standard dose of ARB were randomized to increased ARB regimen (n=132) or amlodipine combination regimen (n=131)."	5.16	Management of home blood pressure by amlodipine combined with angiotensin II receptor blocker in type 2 diabetes. ( Choi, JB; Daida, H; Hayashi, D; Ikeda, S; Imai, Y; Kawamori, R; Kishimoto, J; Kitagawa, A; Miyauchi, K; Murayama, F; Ono, Y; Suwa, S; Tanaka, Y; Watada, H; Yamazaki, T, 2012)
"We studied the effects of treatment with olmesartan/amlodipine and olmesartan/hydrochlorothiazide on inflammatory and metabolic parameters (including new-onset diabetes as a secondary endpoint) in non-diabetic hypertensive patients with metabolic syndrome (MetS)."	5.15	Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. ( Comi-Diaz, C; Martinez-Martin, FJ; Pedrianes-Martin, P; Peiro-Martinez, I; Rodriguez-Rosas, H; Soriano-Perera, P, 2011)
"The safety and efficacy of an amlodipine/olmesartan medoxomil (OM)-based titration regimen was assessed in patients with type 2 diabetes mellitus and hypertension."	5.15	Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. ( Littlejohn, T; Neutel, JM; Qian, C; Ram, CV; Sachson, R; Shojaee, A; Stoakes, KA, 2011)
" To elucidate our hypothesis, we designed a multi-center, open-labeled, randomized trial to compare the antialbuminuric effect between cilnidipine and amlodipine in RAS inhibitor-treated hypertensive (blood pressure [BP]: 130-180/80-110 mmHg) patients with type 2 diabetes and microalbuminuria (urinary albumin/creatinine [Cr] ratio: 30-300 mg/g)."	5.15	Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial. ( Ando, K; Babazono, T; Fujita, T; Kario, K; Matsuoka, H; Nakao, K; Tanaka, S; Ueshima, K, 2011)
"Forty type 2 diabetic patients with hypertension and nephropathy receiving angiotensin receptor II blockers were enrolled and randomly divided into two groups: the efonidipine group was administered efonidipine hydrochloride ethanolate 40 mg/day and the amlodipine group was admin-istered amlodipine besilate 5 mg/day for 12 months."	5.14	Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohhira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Yamaguchi, T, 2009)
"The ADHT (Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial) evaluated the efficacy and safety of adding amlodipine to the treatment regimen of patients with hypertension and diabetes who were already receiving either quinapril or losartan as monotherapy."	5.13	Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial. ( Gregg, AM; Kloner, RA; Neutel, J; Roth, EM; Schwartz, B; Shi, H; Thakker, KM; Weinberger, MH; Weiss, R, 2008)
"The trial was terminated early due to significant benefits on mortality and stroke associated with the amlodipine-based regimen."	5.13	The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. ( Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H, 2008)
"The aim of this study was to compare the efficacy and safety of adding manidipine 20 mg versus amlodipine 10 mg to the treatment of diabetic patients with uncontrolled hypertension and microalbuminuria despite full-dose treatment with a renin-angiotensin system blocker for at least 6 months."	5.13	Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. ( Martinez-Martin, FJ; Saiz-Satjes, M, 2008)
"Based on results of large-scale controlled trials of irbesartan (I), valsartan (V) and amlodipine (A) (PRIME and MARVAL) we carried out the Markov s modeling of their pharmacoeconomic parameters in arterial hypertension (AH) combined with diabetes mellitus type 2 (DM 2) and microalbuminuria (MAU) projected for 8-years perspective."	5.13	[Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus]. ( Belousov, DIu; Belousov, IuB; Shestakova, MV, 2008)
" We hypothesized that a trandolapril/verapamil SR (T/V) fixed-dose combination (FDC) was superior to a benazepril/amlodipine (B/A) FDC for reducing albuminuria in 304 hypertensive diabetic nephropathy patients when treated for 36 weeks."	5.13	Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. ( Bacher, P; Champion, A; Fakouhi, K; Tian, M; Toto, RD, 2008)
"To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden."	5.13	Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. ( Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H, 2008)
"The aim of this study was to compare the effect of valsartan/amlodipine and atenolol/amlodipine combination in preventing the recurrence of atrial fibrillation (AF) in hypertensive diabetic patients with a history of recent paroxysmal atrial fibrillation."	5.13	Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008)
"In addition to reducing urinary protein excretion, losartan at 100 mg daily increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetic nephropathy."	5.12	Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. ( Jin, HM; Pan, Y, 2007)
"Aim of this study was to evaluate the effect of the telmisartan-amlodipine combination at different doses on urinary albumin excretion rate (UAER) in hypertensive diabetic patients with microalbuminuria."	5.12	Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. ( Derosa, G; Destro, M; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007)
" A new clinical trial, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension), is designed to compare the change in urinary albumin to creatinine ratio after 1 year of initial treatment with either amlodipine besylate/benazepril HCl or benazepril HCl/hydrochlorothiazide."	5.11	Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. ( Bakris, GL; McCullough, PA; Toto, RD, 2005)
"Associations between baseline proteinuria and proteinuria reduction by either irbesartan, amlodipine, or control for similar decrements in blood pressure and the cumulative incidence of renal end points were examined using the Kaplan-Meier method in patients enrolled in the Irbesartan Diabetic Nephropathy Trial."	5.11	Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. ( Atkins, RC; Braden, G; Briganti, EM; Champion de Crespigny, PJ; DeFerrari, G; Drury, P; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Wiegmann, TB, 2005)
"The primary objective of this study was to determine whether combination therapy with valsartan 160 mg plus hydrochlorothiazide (HCTZ) 25 mg OD would be more effective than monotherapy with amlodipine 10 mg OD in reducing systolic blood pressure (SBP) in patients with moderate (stage II) hypertension and > or =1 other cardiovascular risk factor or concomitant condition."	5.11	Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. ( Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM, 2005)
"These results suggest that in type 2 diabetes with overt nephropathy, 24-h blood pressure regulation alone is inadequate to reduce macroalbuminuria and additional effects of losartan are crucial for antiproteinuric action."	5.11	Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy. ( Ando, D; Hirawa, N; Tochikubo, O; Umemura, S; Yasuda, G, 2005)
"Three hundred thirty-two patients with type 2 diabetes and microalbuminuria, with or without hypertension, were randomly assigned to 80 mg/d valsartan or 5 mg/d amlodipine for 24 weeks."	5.10	Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. ( Viberti, G; Wheeldon, NM, 2002)
"We selected 453 hypertensive patients with type 2 diabetes and microalbuminuria and randomized them to amlodipine (5 to 15 mg/day), fosinopril (10 to 30 mg/day), or amlodipine plus fosinopril (5/10 to 15/30 mg/day) for a 3-month titration period."	5.10	Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Marasi, G; Mugellini, A; Pasotti, C; Poletti, L; Preti, P; Rinaldi, A; Voglini, C; Zoppi, A, 2002)
"Participants with hypertension and type 2 diabetes mellitus (n=96, 51% black) were randomized after an initial 4 weeks of placebo to double-blind 20 or 40 mg fosinopril or 5 or 10 mg amlodipine daily for 4 weeks in a fixed-dose regimen."	5.10	Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. ( Applegate, WB; Cushman, WC; Deitcher, SR; Franse, LV; Johnson, KC; Kottke-Marchant, K; Pahor, M; Shorr, RI; Somes, GW; Tracy, RP, 2002)
"In this 1-year clinical study, we compared the efficacy and tolerability of amlodipine and nifedipine retard in 64 Chinese Type 2 diabetic patients with hypertension."	5.09	Blood pressure reduction and tolerability of amlodipine versus nifedipine retard in Chinese patients with type 2 diabetes mellitus and hypertension: a randomized 1-year clinical trial. ( Chan, CH; Chan, HC; Ko, GT, 2001)
" The primary aim of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) was to compare the effects of fosinopril and amlodipine on serum lipids and diabetes control in NIDDM patients with hypertension."	5.08	Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. ( Byington, RP; Di Mauro, P; Guarisco, R; Pahor, M; Strollo, F; Strollo, G; Tatti, P, 1998)
"Currently, AIIAs such as losartan represent the only evidence-based treatment strategy for patients with type 2 DM and proteinuria."	4.82	Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. ( Ruilope, LM; Segura, J, 2003)
"SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism."	4.81	[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002)
"Antihypertensive treatment with Amlodipine in addition to standard diabetes therapy improves glycemic control in patients with T2DM and may be an appropriate option in people with diabetes and concomitant hypertension to help maintain euglycemia."	4.12	Antihypertensive treatment improves glycemic control in patients with newly diagnosed type 2 diabetes mellitus: A prospective cohort study. ( Cheng, PC; Huang, CN; Jian, LF; Li, JC; Lin, CL; Wu, YS, 2022)
"Compared with amlodipine, fimasartan increased late-phase glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension."	3.88	Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine. ( Ahn, CH; Cho, YM; Jung, HS; Kim, S; Kwak, SH; Lee, SO; Lim, MH; Mari, A; Park, KS; Roh, E; Yang, YS, 2018)
"to assess in patients with arterial hypertension and type 2 diabetes the effect of perindopril / amlodipine fixed combination on arterial wall stiffness (AWF) and microcirculation, and relationship between AWF parameters and the state microcirculation."	3.88	[Influence of Therapy With Fixed Combination of Perindopril and Amlodipine on Parameters of Elasticity of Main Vessels and Microcirculation in Patients With Arterial Hypertension and Type 2 Diabetes Mellitus]. ( Statsenko, ME; Titarenko, MN; Turkina, SV, 2018)
"Hypertension is a highly prevalent disease and a strong risk factor for cardiovascular disease in industrialized countries in Europe and North America."	3.83	[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk]. ( Kékes, E, 2008)
"To assess effect of combined antihypertensive therapy with lisinopril and amlodipine on circadian blood pressure (BP), insulin resistance (IR), carbohydrate and lipid metabolism in patients with arterial hypertension (AH) and type 2 diabetes mellitus (DM)."	3.80	[Effect of combination antihypertensive therapy on circadian blood pressure and metabolic parameters in patients with type 2 diabetes mellitus]. ( Derevianchenko, MV; Pastukhova, OR; Statsenko, ME, 2014)
" This study was undertaken to compare the efficacy of amlodipine (an inhibitor of L-type calcium channels) and cilnidipine (an inhibitor of both L-type and N-type calcium channels) in patients with hypertension and type II diabetes mellitus."	3.77	Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus. ( Aiba, N; Hara, M; Izumi, T; Kutsuna, T; Masuda, T; Matsumoto, T; Moriya, T; Noda, C; Ogura, MN; Takahira, N, 2011)
" This subanalysis of the Clinical Utility of Caduet in Simultaneously Achieving Blood Pressure and Lipid End Points (CAPABLE) trial studied attainment of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) and the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) goals by 8 flexibly titrated doses (5/10-10/80 mg) of amlodipine/atorvastatin single pill in 494 African Americans with hypertension and dyslipidemia, according to the presence of diabetes +/- the metabolic syndrome."	3.75	Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus. ( Ferdinand, KC; Flack, JM; Jamieson, MJ; Kursun, A; Saunders, E; Shi, H; Victor, R; Watson, K, 2009)
"The irbesartan in Diabetic Nephropathy Trial (IDNT) demonstrated that treatment of patients with type 2 diabetes, hypertension and nephropathy with irbesartan resulted in a 20% relative reduction of the composite endpoint of doubling serum creatinine, end-stage renal disease or death as compared with amlodipine and placebo (antihypertensive standard therapy)."	3.73	[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]. ( Burnier, M; Frei, A; Hess, B; Palmer, AJ, 2006)
"We estimated the cost-effectiveness of irbesartan compared with placebo or amlodipine in the treatment of patients with type 2 diabetes mellitus, hypertension, and overt nephropathy."	3.72	The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. ( Annemans, L; Borenstein, J; Chen, RS; Chiou, CF; Lewis, EJ; Palmer, AJ; Rodby, RA; Roze, S; Sengupta, N; Simon, TA; Smitten, A, 2003)
"The "Irbesartan in Diabetic Nephropathy Trial" (IDNT), demonstrated a reduction in the combined endpoint of doubling of serum creatinine, end-stage renal disease (ESRD) or death compared to control or amlodipine arms in patients with hypertension, type 2 diabetes and overt nephropathy when treated with irbesartan."	3.72	[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension]. ( Annemans, L; Lamotte, M; Palmer, AJ; Ritz, E; Rodby, RA; Roze, S, 2004)
"However, the effects of BDNF on diabetic nephropathy are unknown."	2.80	Assessment of glomerular filtration rate based on alterations of serum brain-derived neurotrophic factor in type 2 diabetic subjects treated with amlodipine/benazepril or valsartan/hydrochlorothiazide. ( Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2015)
"Seventy-six patients with type 2 diabetes and DKD (all with albuminuria and serum creatinine <1."	2.78	Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria. ( Gnudi, L; Hill, B; Karalliedde, J; Maltese, G; Viberti, G, 2013)
"The primary composite outcomes were sudden cardiac death, acute myocardial infarction, stroke, coronary revascularization, or hospitalization for heart failure."	2.78	Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease. ( Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K, 2013)
"Aliskiren was then force-titrated to 300 mg once daily for another 6 weeks."	2.76	Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study. ( Baek, I; Drummond, W; Keefe, DL; Ramos, E; Sirenko, YM, 2011)
"Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR."	2.74	Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009)
" After a 4-week wash-out period, 209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the addition of hydrochlorothiazide 12."	2.74	Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. ( Asmar, R; Baguet, JP; Mallion, JM; Nisse-Durgeat, S; Valensi, P, 2009)
"Seventy type 2 diabetes mellitus patients with hypertension were enrolled and randomly divided into two groups."	2.74	Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohira, M; Oyama, T; Saiki, A; Shirai, K; Yamaguchi, T, 2009)
"Hypertensive patients with type 2 diabetes and microalbuminuria were randomly assigned to valsartan or amlodipine treatment groups for 24 weeks."	2.73	Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART). ( Kashiwagi, A; Maegawa, H; Sawaguchi, M; Uzu, T, 2008)
"Amlodipine and ramipril were added to their previous antihypertensive treatment for 12 weeks."	2.72	Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy. ( Bertoluci, MC; Oliveira, FR; Schmid, H; Schmidt, A; Thomazelli, FC; Uebel, D, 2006)
"Type 2 diabetes is emerging as a major health problem, which tends to cluster with hypertension in individuals at high risk of cardiovascular disease."	2.72	Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. ( Coca, A; Ekman, S; Girerd, X; Hua, T; Jamerson, K; Julius, S; Kjeldsen, SE; Larochelle, P; MacDonald, TM; Mancia, G; McInnes, GT; Schmieder, RE; Schork, MA; Stolt, P; Viskoper, R; Weber, MA; Widimský, J; Zanchetti, A, 2006)
"The coexistence of type 2 diabetes mellitus and hypertension increases the risk of cardiovascular diseases."	2.72	Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J). ( Daida, H; Hayashi, D; Ikeda, S; Imai, Y; Kawamori, R; Kishimoto, J; Kitagawa, A; Miyauchi, K; Tanaka, Y; Yamazaki, T, 2006)
"Hypertension in type 2 diabetes represents a strong risk factor for cardiovascular events."	2.72	The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients. ( Hassan, H; Negro, R, 2006)
"The primary outcomes of the Irbesartan Diabetic Nephropathy Trial were doubling of serum creatinine levels, end-stage renal disease, and death from any cause."	2.71	Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. ( Berl, T; Drury, PL; Esmatjes, E; Goldhaber, SZ; Hricik, D; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Parikh, CR; Pfeffer, MA; Porush, JG; Raz, I; Rouleau, JL; Vanhille, P; Wiegmann, TB; Wolfe, BM, 2003)
" at the same dosage for 6 weeks in three crossover periods each separated by a 2-week placebo wash-out period (3x3 latin square)."	2.71	Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients. ( Corradi, L; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2003)
"All participants had baseline diabetic nephropathy, overt proteinuria, and hypertension and were recruited between 1996 and 1999."	2.71	Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy. ( Bostom, AG; Friedman, AN; Hunsicker, LG; Selhub, J, 2005)
" Blood samples were collected after administration of amlodipine and AUC, Cmax, and tmax were determined."	2.70	Comparative pharmacokinetics and pharmacodynamics of amlodipine in hypertensive patients with and without type II diabetes mellitus. ( Alonso, A; Baltodano, NM; Chung, M; Epstein, M; Gaffney, M; Preston, RA, 2001)
"Amlodipine treatment caused a significant decrease in IMT compared with control (-0."	2.69	Effect of calcium channel blocker amlodipine on the intimal-medial thickness of carotid arterial wall in type 2 diabetes. ( Koshiyama, H; Minamikawa, J; Tanaka, S, 1999)
"Diabetic nephropathy is the most common cause of end-stage renal disease in the developed world."	2.69	The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. ( Anzalone, DA; Atkins, RC; Clarke, WR; Hunsicker, LG; Lewis, EJ; Ritz, E; Rodby, RA; Rohde, RD, 2000)
"Of the hypertensive NIDDM patients attending the outpatient's clinic of the internal medicine departments of the University of Padova and Sassari, 44 participated in the present study."	2.68	Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. ( Brocco, E; Carraro, A; Cernigoi, AM; Fioretto, P; Fresu, P; Frigato, F; Maioli, M; Muollo, B; Nosadini, R; Tonolo, G; Velussi, M; Zolli, M, 1996)
"Less than 10% of parathyroid carcinomas are non-functional, and as such, they have been rarely reported in the literature."	2.45	Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. ( Lewis, JS; Wilkins, BJ, 2009)
" Although the overall goal of these drugs remains the blockade of RAS activation, their individual targets in this system vary and may substantially influence the clinical benefit derived from the long term use of these substances."	2.45	Angiotensin II type 1 receptor blockade: high hopes sent back to reality? ( Divchev, D; Grothusen, A; Luchtefeld, M; Schieffer, B, 2009)
"Proteinuria was reduced on average by 33% in the irbesartan group as compared with 6% in the amlodipine group and 10% in the placebo group."	2.42	Treatment of diabetic nephropathy with angiotensin II receptor antagonist. ( Lewis, EJ; Lewis, JB, 2003)
" Therefore, the results of valsartan and amlodipine tablets combined with alpha-lipoic acid on total antioxidant capacity (T-AOC) need to be investigated."	1.91	Effects of Valsartan and Amlodipine Tablets Combined with α-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy. ( Su, F; Xia, Q, 2023)
"Nifedipine was resumed during periodontal treatment when the patient's hypertension worsened."	1.62	Treatment of calcium channel blocker-induced gingival overgrowth without modifying medication. ( Miyashita, Y; Morikawa, S; Nakagawa, T; Nasu, M, 2021)
"To evaluate, in patients with type 2 diabetes and hypertension, the effects of 6 months treatment with canagliflozin, or perindopril, an angiotensin converting enzyme inhibitor, on central BP and carotid-femoral pulse wave velocity (cfPWV)."	1.51	Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril. ( Ramirez, AJ; Sanchez, MJ; Sanchez, RA, 2019)
"The Irbesartan Diabetic Nephropathy Trial (IDNT) demonstrated that irbesartan significantly slowed established Type 2 diabetic nephropathy progression."	1.38	Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. ( Bain, SC; Bilous, RW; Evans, M; Hogan, S, 2012)
"Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity."	1.36	Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010)
"In the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial, the risk of new-onset diabetes was reported to be 23% lower among patients initiating therapy with valsartan versus amlodipine."	1.34	Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. ( Edelsberg, J; Jamerson, K; Khan, ZM; Kjeldsen, SE; Oster, G; Vincze, G; Weycker, D, 2007)
"Ramipril treatment was associated with a significantly lower risk of DM in African Americans with hypertensive kidney disease than amlodipine or metoprolol treatment."	1.33	Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. ( Agodoa, LY; Appel, LJ; Cheek, D; Contreras, G; Gassman, J; Lash, JP; Miller, ER; Randall, OS; Thornley-Brown, D; Wang, X; Wright, JT, 2006)
"Imidapril treatment significantly decreased urinary albumin excretions and improved glomerulosclerosis of OLETF rats, while amlodipine failed to improve nephropathy of OLETF rats despite lowering of blood pressure."	1.31	Role of intrarenal angiotensin-converting enzyme in nephropathy of type II diabetic rats. ( Iwao, H; Kim, S; Taniguchi, M; Zhan, Y, 2002)

Research

Studies (164)

Authors

Clinical Trials (23)

Trial Overview

Trial Outcomes

Diastolic Blood Pressure

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	6 (3.66)	18.2507
2000's	80 (48.78)	29.6817
2010's	72 (43.90)	24.3611
2020's	6 (3.66)	2.80

Authors	Studies
Cicero, AFG	1
Fogacci, F	1
Rizzoli, E	1
Giovannini, M	1
D'Addato, S	1
Borghi, C	1
Li, JC	1
Cheng, PC	1
Huang, CN	1
Jian, LF	1
Wu, YS	1
Lin, CL	1
Su, F	1
Xia, Q	1
Tchernev, G	1
Morikawa, S	1
Nasu, M	1
Miyashita, Y	3
Nakagawa, T	1
Aung, TKK	1
Chuah, TY	1
Chua, MWJ	1
Moon, JS	1
Won, KC	1
Kim, HJ	1
Han, SJ	1
Kim, DJ	1
Jang, HC	2
Lim, S	1
Choi, SH	1
Kim, YH	1
Shin, DH	1
Kim, SH	1
Kim, TH	1
Ahn, YB	1
Ko, SH	1
Kim, NH	1
Seo, JA	1
Kim, HY	1
Lee, KW	2
Hanon, O	2
Caillard, L	2
Chaussade, E	2
Hernandorena, I	1
Boully, C	2
Hwang, YC	1
Yoon, KH	1
Cha, BS	1
Min, KW	1
Chung, CH	1
Lee, MK	1
Yang, YS	1
Lim, MH	1
Lee, SO	1
Roh, E	1
Ahn, CH	1
Kwak, SH	1
Cho, YM	1
Kim, S	2
Mari, A	1
Park, KS	1
Jung, HS	1
Statsenko, ME	7
Turkina, SV	1
Titarenko, MN	3
Bolanle, IO	1
Omogbai, EKI	1
Bafor, EE	1
Ramirez, AJ	1
Sanchez, MJ	1
Sanchez, RA	1
Imaizumi, S	1
Shiga, Y	1
Ogawa, M	1
Sako, H	1
Nagata, Y	1
Matsunaga, A	1
Shirotani, T	1
Hoshino, F	1
Yahiro, E	1
Uehara, Y	1
Morito, N	1
Tanigawa, H	1
Shimono, D	1
Fukushima, M	1
Sugihara, H	1
Norimatsu, K	1
Kusumoto, T	1
Saku, K	1
Miura, SI	1
van der Merwe, WM	1
Sobngwi, E	1
Mfeukeu-Kuate, L	1
Kouam, M	1
Tankeu, AT	1
Nganou-Gnindjio, CN	1
Hamadou, B	1
Etoa, M	1
Ngassam, E	1
Nkamgna, A	1
Dehayem, MY	1
Kaze, FF	1
Kengne, AP	1
Mbanya, JC	1
Irons, BK	1
Trujillo, A	1
Seifert, CF	1
Simoni, JS	1
Doctolero, S	1
Abo-Salem, E	1
Meyerrose, GE	1
Eckert, S	1
Freytag, SB	1
Müller, A	1
Klebs, SH	1
Karalliedde, J	2
Maltese, G	1
Hill, B	1
Viberti, G	3
Gnudi, L	1
Ando, K	2
Ueshima, K	4
Tanaka, S	3
Kosugi, S	1
Sato, T	1
Matsuoka, H	2
Nakao, K	5
Fujita, T	2
Takagi, H	1
Umemoto, T	1
Spinar, J	1
Vitovec, J	1
Soucek, M	1
Yamashita, K	2
Kondo, T	2
Muramatsu, T	2
Matsushita, K	2
Nagahiro, T	1
Maeda, K	2
Shintani, S	2
Murohara, T	2
Derevianchenko, MV	4
Ostrovskiĭ, OV	1
Shvets, MK	1
Bondarev, AM	1
Fogari, R	8
Derosa, G	9
Zoppi, A	8
Lazzari, P	7
D'Angelo, A	3
Mugellini, A	10
Sweiss, N	1
Sharma, K	1
Mihaleva, AV	1
Pozzobon, CR	2
Gismondi, RA	2
Bedirian, R	2
Ladeira, MC	2
Neves, MF	2
Oigman, W	2
Tabur, S	1
Oğuz, E	1
Sabuncu, T	1
Korkmaz, H	1
Çelik, H	1
Yilmaz, MI	2
Sonmez, A	2
Saglam, M	2
Kurt, YG	1
Unal, HU	1
Karaman, M	1
Gok, M	1
Cetinkaya, H	1
Eyileten, T	2
Oguz, Y	1
Vural, A	1
Mallamaci, F	1
Zoccali, C	1
Labourée, F	1
Cochiello, S	1
Pastukhova, OR	1
Lee, IT	2
Sheu, WH	2
Hung, YJ	2
Chen, JF	2
Wang, CY	2
Lee, WJ	2
Pesce, RM	2
Maffioli, P	4
Ruilope, LM	3
Derevyanchenko, MV	1
Redon, J	2
Pichler, G	2
Kang, MK	1
Chung, WB	1
Hong, SK	1
Kim, OR	1
Ihm, SH	1
Chang, K	1
Seung, KB	1
Hatalova, K	1
Pella, D	1
Sidlo, R	1
Hatala, R	1
Simonyi, G	1
Saiz-Satjes, M	2
Martinez-Martin, FJ	3
Roca-Cusachs, A	1
Kjeldsen, SE	4
McInnes, GT	4
Mancia, G	2
Hua, TA	1
Julius, S	2
Weber, MA	3
Coca, A	2
Girerd, X	2
Jamerson, K	4
Larochelle, P	2
Macdonald, T	1
Schmieder, RE	2
Anthony Schork, M	1
Viskoper, R	2
Widimsky, J	2
Zanchetti, A	2
Uzu, T	2
Sawaguchi, M	2
Maegawa, H	2
Kashiwagi, A	2
Kékes, E	1
Kloner, RA	1
Neutel, J	1
Roth, EM	1
Weiss, R	1
Weinberger, MH	1
Thakker, KM	1
Schwartz, B	1
Shi, H	2
Gregg, AM	1
Ostergren, J	1
Poulter, NR	2
Sever, PS	2
Dahlöf, B	3
Wedel, H	2
Beevers, G	1
Caulfield, M	1
Collins, R	1
Kristinsson, A	1
Mehlsen, J	1
Nieminen, M	1
O'Brien, E	1
Ikeda, H	1
Minamikawa, J	2
Nakamura, Y	1
Honjo, S	1
Hamamoto, Y	1
Wada, Y	1
Nabe, K	1
Koshiyama, H	2
Belousov, IuB	1
Shestakova, MV	1
Belousov, DIu	1
Toto, RD	3
Tian, M	1
Fakouhi, K	1
Champion, A	1
Bacher, P	1
Guo, LL	1
Pan, Y	2
Jin, HM	2
Escobar, C	1
Barrios, V	1
Saruta, T	4
Hayashi, K	2
Ogihara, T	3
Fukui, T	1
Fukiyama, K	1
Baguet, JP	1
Asmar, R	1
Valensi, P	1
Nisse-Durgeat, S	1
Mallion, JM	1
Tkacheva, ON	1
Barabashkina, AV	1
Novikova, IM	1
Runikhina, NK	1
Wilkins, BJ	1
Lewis, JS	1
Sasaki, H	1
Saiki, A	2
Endo, K	2
Ban, N	2
Yamaguchi, T	2
Kawana, H	2
Nagayama, D	2
Ohhira, M	1
Oyama, T	2
Shirai, K	2
Ferdinand, KC	1
Flack, JM	1
Saunders, E	1
Victor, R	1
Watson, K	1
Kursun, A	1
Jamieson, MJ	1
Ohira, M	1
Grothusen, A	1
Divchev, D	1
Luchtefeld, M	1
Schieffer, B	1
Oparil, S	1
Chrysant, SG	1
Melino, M	1
Lee, J	1
Karki, S	1
Heyrman, R	1
Masuda, T	1
Ogura, MN	1
Moriya, T	1
Takahira, N	1
Matsumoto, T	1
Kutsuna, T	1
Hara, M	1
Aiba, N	1
Noda, C	1
Izumi, T	1
Fujimoto, A	3
Hirata, M	1
Oba, K	1
Yasuno, S	2
Carrero, JJ	1
Martín-Ventura, JL	1
Celik, T	1
Yaman, H	1
Yenicesu, M	1
Moreno, JA	1
Egido, J	1
Blanco-Colio, LM	1
Rodriguez-Rosas, H	1
Peiro-Martinez, I	1
Soriano-Perera, P	1
Pedrianes-Martin, P	1
Comi-Diaz, C	1
Okura, T	1
Kojima, M	2
Machida, H	1
Sugiyama, M	1
Kato, T	1
Komada, T	1
Miyazaki, T	1
Ninomiya, T	1
Ichikawa, T	1
Nakatani, K	1
Watanabe, Y	1
Dohi, Y	2
Ito, M	2
Kimura, G	2
Holtkamp, FA	1
de Zeeuw, D	1
de Graeff, PA	1
Laverman, GD	1
Berl, T	3
Remuzzi, G	1
Packham, D	1
Lewis, JB	5
Parving, HH	1
Lambers Heerspink, HJ	1
Balink, H	1
Hemmelder, MH	1
de Graaf, W	1
Grond, J	1
Ram, CV	1
Sachson, R	1
Littlejohn, T	1
Qian, C	1
Shojaee, A	2
Stoakes, KA	1
Neutel, JM	2
Babazono, T	1
Kario, K	1
Hiroo, K	1
Oda, T	1
Kushiyama, T	1
Higashi, K	1
Yamamoto, K	1
Destro, M	2
Corradi, L	4
Preti, P	6
Drummond, W	1
Sirenko, YM	1
Ramos, E	1
Baek, I	1
Keefe, DL	2
Monti, C	1
Townsend, RR	1
Forker, AD	1
Bhosekar, V	1
Yadao, A	1
Evans, M	1
Bain, SC	1
Hogan, S	1
Bilous, RW	1
Ichimiya, S	1
Ohno, M	1
Sone, T	1
Ikeda, N	1
Watarai, M	1
Sharma, AM	1
Bakris, G	1
Littlejohn, TW	1
Kobe, M	1
Ting, N	1
Ley, L	1
Ogawa, H	1
Kim-Mitsuyama, S	1
Matsui, K	1
Jinnouchi, T	1
Jinnouchi, H	1
Arakawa, K	1
Abe, M	1
Maruyama, N	1
Suzuki, H	2
Fujii, Y	1
Yoshida, Y	1
Okada, K	1
Soma, M	1
Daikuhara, H	1
Kikuchi, F	1
Ishida, T	1
Miyauchi, K	2
Yamazaki, T	2
Watada, H	2
Tanaka, Y	2
Kawamori, R	3
Imai, Y	2
Ikeda, S	2
Kitagawa, A	2
Ono, Y	1
Murayama, F	1
Choi, JB	1
Suwa, S	1
Hayashi, D	2
Kishimoto, J	2
Daida, H	2
Ohashi, M	1
Chatzikyrkou, C	1
Menne, J	1
Nesbitt, SD	1
Maa, JF	1
Weir, MR	1
Wheeldon, NM	1
Rinaldi, A	2
Pasotti, C	1
Poletti, L	1
Marasi, G	1
Voglini, C	1
Bernadet-Monrozies, P	1
Rostaing, L	1
Kamar, N	1
Durand, D	1
Kuriyama, S	1
Tomonari, H	1
Tokudome, G	1
Horiguchi, M	1
Hayashi, H	1
Kobayashi, H	1
Ishikawa, M	1
Hosoya, T	1
Hunsicker, LG	6
Pfeffer, MA	1
Porush, JG	1
Rouleau, JL	1
Drury, PL	1
Esmatjes, E	1
Hricik, D	1
Parikh, CR	1
Raz, I	2
Vanhille, P	1
Wiegmann, TB	2
Wolfe, BM	1
Locatelli, F	2
Goldhaber, SZ	1
Lewis, EJ	7
Ko, GT	2
Chan, HC	2
Fogari, E	2
Lopatin, IuM	1
Kirakozov, DA	1
Rodby, RA	4
Chiou, CF	1
Borenstein, J	1
Smitten, A	1
Sengupta, N	1
Palmer, AJ	3
Roze, S	2
Annemans, L	2
Simon, TA	1
Chen, RS	1
Krol, E	1
Agueel, R	1
Banue, S	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide on Blood Pressure Control in Newly Diagnosed Type 2 Diabetes Individuals With Hypertension[NCT03747978]	Phase 4	30 participants (Actual)	Interventional	2016-10-01	Completed
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293]		125 participants (Anticipated)	Observational	2021-05-19	Recruiting
A 24-week Study to Evaluate the Effectiveness of Valsartan in Combination With Hydrochlorothiazide Versus Amlodipine on Arterial Compliance in Patients With Hypertension, Type 2 Diabetes and Albuminuria[NCT00171561]	Phase 4	144 participants (Actual)	Interventional	2003-03-31	Completed
Evaluation of Hematologic Patients - Training Protocol[NCT00001715]		898 participants (Actual)	Observational	1998-04-21	Completed
The Novel Antihypertensive Goal Of hYpertension With diAbetes - Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study[NCT00129233]	Phase 4	1,150 participants (Actual)	Interventional	2004-10-31	Completed
[NCT01738945]	Phase 4	32 participants (Actual)	Interventional	2008-02-29	Completed
Evaluation of Some Emerging Biomarkers of Cardiovascular Risk Stratification in Hypertensive Patients: a 5-years Follow-up[NCT02064218]		0 participants	Observational	2007-11-30	Recruiting
Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients With Blood Pressure Not Controlled by Amlodipine: Effects on Echocardiographic Parameters, Vascular Stiffness and Endothelial Function.[NCT01603940]	Phase 4	30 participants (Actual)	Interventional	2012-05-31	Completed
The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART)[NCT00202618]	Phase 4	160 participants	Interventional	2003-12-31	Recruiting
The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combine Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension[NCT00921570]	Phase 4	105 participants (Actual)	Interventional	2008-02-29	Completed
A 12-week, Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy & Safety of Aliskiren in Patients With Diabetes & Hypertension Not Adequately Responsive to the Combination of Valsartan 160 mg & Hydrochlorothiazide 25 [NCT00219102]	Phase 3	336 participants	Interventional	2005-06-30	Completed
Medication Adherence Given Individual SystemCHANGE(TM) in Advancing Nephropathy (MAGICIAN) Pilot Study[NCT04616612]		150 participants (Anticipated)	Interventional	2021-12-15	Recruiting
The Study Comparing the Incidence of Cardiovascular Events Between High-dose ARB Monotherapy and Combination Therapy With ARB and Calcium Channel Blocker in Japanese Elderly Hypertensive Patients at High Cardiovascular Risk[NCT00134160]	Phase 4	1,000 participants (Anticipated)	Interventional	2005-08-31	Completed
Efficacy and Safety of Two Fixed-combination Antihypertensive Regimens, Amtrel® and Co-Diovan® in Type 2 Diabetes Hypertension Patients With Microalbuminuria[NCT01375322]	Phase 4	226 participants (Actual)	Interventional	2007-06-30	Completed
A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy[NCT00791258]	Phase 4	999 participants (Actual)	Interventional	2008-11-30	Completed
[NCT00000542]	Phase 3	0 participants	Interventional	1993-08-31	Completed
Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy[NCT00295555]	Phase 4	98 participants (Actual)	Interventional	2004-01-31	Completed
[NCT00021918]		0 participants	Observational	2001-04-30	Completed
Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure.[NCT00456963]	Phase 4	3,000 participants (Anticipated)	Interventional	2007-09-30	Terminated (stopped due to Because of delay in approval of the protocol by a number of Ethics Commitees the trial was terminated on March 4, 2010. No patient had received any study drug.)
Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension[NCT01444833]		35 participants (Anticipated)	Interventional	2008-10-31	Recruiting
A Double-blind, Randomized, Multicenter Study to Evaluate the Effectiveness of the Combination of Valsartan & Amlodipine in Hypertensive Patients Not Controlled on Monotherapy[NCT00327145]	Phase 3	894 participants (Actual)	Interventional	2006-03-31	Completed
Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323]	Phase 2	60 participants (Anticipated)	Interventional	2021-05-25	Recruiting
Determinants of Diabetic Nephropathy in American Indians[NCT01878045]		141 participants (Actual)	Observational	2013-11-07	Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Compare both group effects on diastolic blood pressure. (NCT01603940)
Timeframe: 12 weeks

Endothelial Function

Intervention	mmHg (Median)
Losartan	80
Benazepril	82

Access endothelial function by brachial flow-mediated vasodilation (FMD) and compare it between groups (losartan and benazepril) and its relationship to current statin use. (NCT01603940)
Timeframe: 12 weeks

Systolic Blood Pressure

Intervention	percentage of maximal vasodilation (Median)
Losartan	9.4
Benazepril	8.8

Compare both groups effects on systolic blood pressure. (NCT01603940)
Timeframe: 12 weeks

Vascular Stiffness

Intervention	mmHg (Median)
Losartan	134
Benazepril	139

Access vascular stiffness by pulse wave velocity and compare it between groups (losartan and benazepril). (NCT01603940)
Timeframe: 12 weeks.

Vascular Stiffness by Augmentation Index

Intervention	m/s (Median)
Losartan	8.5
Benazepril	8.5

Estimate vascular stiffness by measuring augmentation index and compare it between losartan and benazepril groups. (NCT01603940)
Timeframe: 12 weeks

The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks

The Percentage of Subjects Achieving Seated Diastolic BP Goal (<90 mmHg for Non-diabetics or < 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks

Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values

Intervention	percentage of augmentation pressure (Median)
Losartan	28
Benazepril	35

Intervention	Percentage of participants (Number)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	75.8

Intervention	Percentage of participants (Number)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	84.3

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8 a.m. to 4 p.m. Nighttime is defined as 10 p.m. to 6 a.m. (NCT00791258)
Timeframe: Baseline to 12 weeks

Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values

Intervention	mm Hg (Mean)
	24-hour mean systolic blood pressure	Mean daytime systolic blood pressure	Mean nighttime systolic blood pressure	Systolic blood pressure - last 2 hours of dose	Systolic blood pressure - last 4 hours of dose	Systolic blood pressure - last 6 hours of dose	24-hour mean diastolic blood pressure	Mean daytime diastolic blood pressure	Mean nighttime diastolic blood pressure	Diastolic blood pressure - last 2 hours of dose	Diastolic blood pressure - last 4 hours of dose	Diastolic blood pressure - last 6 hours of dose
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	-14.8	-16.3	-12.5	-13.6	-13.0	-12.6	-9.4	-10.6	-7.6	-8.6	-8.0	-7.7

Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks

Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Intervention	mm Hg (Mean)
	24-hour mean systolic blood pressure	Mean daytime systolic blood pressure	Mean nighttime systolic blood pressure	Systolic blood pressure - last 2 hours of dose	Systolic blood pressure - last 4 hours of dose	Systolic blood pressure - last 6 hours of dose	24-hour mean diastolic blood pressure	Mean daytime diastolic blood pressure	Mean nighttime diastolic blood pressure	Diastolic blood pressure - last 2 hours of dose	Diastolic blood pressure - last 4 hours of dose	Diastolic blood pressure - last 6 hours of dose
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	-21.0	-23.2	-17.5	-19.6	-18.2	-17.9	-13.3	-15.0	-11.1	-12.3	-11.6	-11.3

Intervention	mm Hg (Mean)
	4 weeks, N=975	8 weeks, N=929	12 weeks, N=865	16 weeks, N=797	20 weeks, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	-8.1	-9.1	-11.9	-14.6	-14.5

Intervention	mm Hg (Mean)
	4 weeks, N=975	8 weeks, N=929	12 weeks, N=865	16 weeks, N=797	20 weeks, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	-14.6	-16.6	-21.8	-26.0	-26.8

Intervention	Percentage of Participants (Number)
	4 weeks: <140/90 mm Hg, N=230	4 weeks: <135/80 mm Hg, N=230	4 weeks: <130/80 mm Hg, N=230	4 weeks: <120/80 mm Hg, N=230	8 weeks: <140/90 mm Hg, N=231	8 weeks: <135/80 mm Hg, N=231	8 weeks: <130/80 mm Hg, N=232	8 weeks: <120/80 mm Hg, N=232	12 weeks: <140/90mm Hg, N=232	12 weeks: <135/80 mm Hg, N=232	12 weeks: <130/80 mm Hg, N=232	12 weeks: <120/80 mm Hg, N=232	16 weeks: <140/90 mm Hg, N=232	16 weeks: <135/80 mm Hg, N=232	16 weeks: <130/80 mm Hg, N=232	16 weeks: <120/80 mm Hg, N=232	20 weeks: <140/90 mm Hg, N=232	20 weeks: <135/80 mm Hg, N=232	20 weeks: <130/80 mm Hg, N=232	20 weeks: <120/80 mm Hg, N=232
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	45.7	14.8	10.4	3.9	55.0	23.8	20.8	10.4	68.5	38.4	35.8	16.4	80.6	49.1	47.4	30.6	86.6	57.8	55.2	39.7

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=230	4 weeks: <85 mm Hg, N=230	4 weeks: <80 mm Hg, N=230	8 weeks: <90 mm Hg, N=231	8 weeks: <85 mm Hg, N=231	8 weeks: <80 mm Hg, N=231	12 weeks: <90 mm Hg, N=232	12 weeks: <85 mm Hg, N=232	12 weeks: <80 mm Hg, N=232	16 weeks: <90 mm Hg, N=232	16 weeks: <85 mm Hg, N=232	16 weeks: <80 mm Hg, N=232	20 weeks: <90 mm Hg, N=232	20 weeks: <85 mm Hg, N=232	20 weeks: <80 mm Hg, N=232
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	60.9	42.2	19.6	71.9	53.7	30.3	82.3	66.0	45.3	92.2	76.3	55.2	94.8	80.6	61.2

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=230	4 weeks: >10 and ≤ 15 mm Hg, N=230	4 weeks: >15 and ≤ 20 mm Hg, N=230	4 weeks: >20 mm Hg, N=230	8 weeks: ≤ 10 mm Hg, N=220	8 weeks: >10 and ≤ 15 mm Hg, N=220	8 weeks: >15 and ≤ 20 mm Hg, N=220	8 weeks: >20 mm Hg, N=220	12 weeks: ≤ 10 mm Hg, N=208	12 weeks: >10 and ≤15 mm Hg, N=208	12 weeks: >15 and ≤ 20 mm Hg, N=208	12 weeks: >20 mm Hg, N=208	16 weeks: ≤ 10 mm Hg, N=199	16 weeks: >10 and ≤ 15 mm Hg, N=199	16 weeks: >15 and ≤ 20 mm Hg, N=199	16 weeks: >20 mm Hg, N=199	20 weeks: ≤ 10 mm Hg, N=189	20 weeks: >10 and ≤ 15 mm Hg, N=189	20 weeks: >15 and ≤ 20 mm Hg, N=189	20 weeks: >20 mm Hg, N=189
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	70.0	17.8	7.9	4.4	66.8	15.0	10.9	7.3	54.8	21.2	12.0	12.0	38.7	19.6	23.1	18.6	36.0	19.6	20.6	23.8

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=230	4 weeks: <135 mm Hg, N=230	4 weeks: <130 mm Hg, N=230	4 weeks: <120 mm Hg, N=230	8 weeks: <140 mm Hg, N=231	8 weeks: <135 mm Hg, N=231	8 weeks: <130 mm Hg, N=231	8 weeks: <120 mm Hg, N=231	12 weeks: <140 mm Hg, N=232	12 weeks: <135 mm Hg, N=232	12 weeks: <130 mm Hg, N=232	12 weeks: <120 mm Hg, N=232	16 weeks: <140 mm Hg, N=232	16 weeks: <135 mm Hg, N=232	16 weeks: <130 mm Hg, N=232	16 weeks: <120 mm Hg, N=232	20 weeks: <140 mm Hg, N=232	20 weeks: <135 mm Hg, N=232	20 weeks: <130 mm Hg, N=232	20 weeks: <120 mm Hg, N=232
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	51.7	34.4	19.6	5.7	62.3	44.6	33.8	13.0	76.3	59.1	47.0	19.8	84.9	71.1	61.2	34.1	91.0	80.6	71.1	44.4

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=230	4 weeks: >15 and ≤ 30 mm Hg, N=230	4 weeks: >30 and ≤ 45 mm Hg, N=230	4 weeks: >45 mm Hg, N=230	8 weeks: ≤ 15 mm Hg, N=220	8 weeks: >15 and ≤ 30 mm Hg, N=220	8 weeks: >30 and ≤ 45 mm Hg, N=220	8 weeks: >45 mm Hg, N=220	12 weeks: ≤ 15 mm Hg, N=208	12 weeks: >15 and ≤ 30 mm Hg, N=208	12 weeks: >30 and ≤ 45 mm Hg, N=208	12 weeks: >45 mm Hg, N=208	16 weeks: ≤ 15 mm Hg, N=199	16 weeks: >15 and ≤ 30 mm Hg, N=199	16 weeks: >30 and ≤ 45 mm Hg, N=199	16 weeks: >45 mm Hg, N=199	20 weeks: ≤ 15 mm Hg, N=189	20 weeks: >15 and ≤ 30 mm Hg, N=189	20 weeks: >30 and ≤ 45 mm Hg, N=189	20 weeks: >45 mm Hg, N=189
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	60.0	32.2	7.4	0.4	53.6	38.2	7.3	0.9	38.9	41.8	16.4	2.9	30.7	37.2	25.1	7.0	24.3	37.6	29.6	8.5

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=128	4 weeks: <85 mm Hg, N=128	4 weeks: <80 mm Hg, N=128	8 weeks: <90 mm Hg, N=128	8 weeks: <85 mm Hg, N=128	8 weeks: <80 mm Hg, N=128	12 weeks: <90 mm Hg, N=128	12 weeks: <85 mm Hg, N=128	12 weeks: <80 mm Hg, N=128	16 weeks: <90 mm Hg, N=128	16 weeks: <85 mm Hg, N=128	16 weeks: <80 mm Hg, N=128	20 weeks: <90 mm Hg, N=128	20 weeks: <85 mm Hg, N=128	20 weeks: <80 mm Hg, N=128
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	83.6	69.5	45.3	89.1	79.7	60.2	95.3	87.5	71.1	96.9	93.0	82.0	96.9	93.0	85.2

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=126	4 weeks: >10 and ≤ 15 mm Hg, N=126	4 weeks: >15 and ≤ 20 mm Hg, N=126	4 weeks: >20 mm Hg, N=126	8 weeks: ≤ 10 mm Hg, N=123	8 weeks: >10 and ≤ 15 mm Hg, N=123	8 weeks: >15 and ≤ 20 mm Hg, N=123	8 weeks: >20 mm Hg, N=123	12 weeks: ≤ 10 mm Hg, N=120	12 weeks: >10 and ≤15 mm Hg, N=120	12 weeks: >15 and ≤ 20 mm Hg, N=120	12 weeks: >20 mm Hg, N=120	16 weeks: ≤ 10 mm Hg, N=112	16 weeks: >10 and ≤ 15 mm Hg, N=112	16 weeks: >15 and ≤ 20 mm Hg, N=112	16 weeks: >20 mm Hg, N=112	20 weeks: ≤ 10 mm Hg, N=105	20 weeks: >10 and ≤ 15 mm Hg, N=105	20 weeks: >15 and ≤ 20 mm Hg, N=105	20 weeks: >20 mm Hg, N=105
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	47.6	26.2	13.5	12.7	38.2	24.4	22.0	15.5	33.3	25.8	19.2	21.7	27.7	17.0	20.5	34.8	36.2	16.2	18.1	29.5

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=128	4 weeks: <135 mm Hg, N=128	4 weeks: <130 mm Hg, N=128	4 weeks: <120 mm Hg, N=128	8 weeks: <140 mm Hg, N=128	8 weeks: <135 mm Hg, N=128	8 weeks: <130 mm Hg, N=128	8 weeks: <120 mm Hg, N=128	12 weeks: <140 mm Hg, N=128	12 weeks: <135 mm Hg, N=128	12 weeks: <130 mm Hg, N=128	12 weeks: <120 mm Hg, N=128	16 weeks: <140 mm Hg, N=128	16 weeks: <135 mm Hg, N=128	16 weeks: <130 mm Hg, N=128	16 weeks: <120 mm Hg, N=128	20 weeks: <140 mm Hg, N=128	20 weeks: <135 mm Hg, N=128	20 weeks: <130 mm Hg, N=128	20 weeks: <120 mm Hg, N=128
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	64.8	51.6	35.2	11.7	76.6	67.2	51.6	25.0	89.1	78.9	66.4	38.3	95.3	89.8	81.3	47.7	97.7	93.0	85.9	51.6

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=126	4 weeks: >15 and ≤ 30 mm Hg, N=126	4 weeks: >30 and ≤ 45 mm Hg, N=126	4 weeks: >45 mm Hg, N=126	8 weeks: ≤ 15 mm Hg, N=123	8 weeks: >15 and ≤ 30 mm Hg, N=123	8 weeks: >30 and ≤ 45 mm Hg, N=123	8 weeks: >45 mm Hg, N=123	12 weeks: ≤ 15 mm Hg, N=120	12 weeks: >15 and ≤ 30 mm Hg, N=120	12 weeks: >30 and ≤ 45 mm Hg, N=120	12 weeks: >45 mm Hg, N=120	16 weeks: ≤ 15 mm Hg, N=112	16 weeks: >15 and ≤ 30 mm Hg, N=112	16 weeks: >30 and ≤ 45 mm Hg, N=112	16 weeks: >45 mm Hg, N=112	20 weeks: ≤ 15 mm Hg, N=105	20 weeks: >15 and ≤ 30 mm Hg, N=105	20 weeks: >30 and ≤ 45 mm Hg, N=105	20 weeks: >45 mm Hg, N=105
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	43.7	38.1	15.9	2.4	40.7	35.8	22.0	1.6	28.3	39.2	27.5	5.0	20.5	36.6	31.3	11.6	29.5	28.6	33.3	8.6

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=227	4 weeks: <85 mm Hg, N=227	4 weeks: <80 mm Hg, N=227	8 weeks: <90 mm Hg, N=227	8 weeks: <85 mm Hg, N=227	8 weeks: <80 mm Hg, N=227	12 weeks: <90 mm Hg, N=227	12 weeks: <85 mm Hg, N=227	12 weeks: <80 mm Hg, N=227	16 weeks: <90 mm Hg, N=227	16 weeks: <85 mm Hg, N=227	16 weeks: <80 mm Hg, N=227	20 weeks: <90 mm Hg, N=227	20 weeks: <85 mm Hg, N=227	20 weeks: <80 mm Hg, N=227
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	88.1	76.7	58.2	92.1	83.7	71.8	97.4	92.1	80.2	98.7	94.3	88.6	98.7	95.2	90.3

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=224	4 weeks: >10 and ≤ 15 mm Hg, N=224	4 weeks: >15 and ≤ 20 mm Hg, N=224	4 weeks: >20 mm Hg, N=224	8 weeks: ≤ 10 mm Hg, N=217	8 weeks: >10 and ≤ 15 mm Hg, N=217	8 weeks: >15 and ≤ 20 mm Hg, N=217	8 weeks: >20 mm Hg, N=217	12 weeks: ≤ 10 mm Hg, N=199	12 weeks: >10 and ≤15 mm Hg, N=199	12 weeks: >15 and ≤ 20 mm Hg, N=199	12 weeks: >20 mm Hg, N=199	16 weeks: ≤ 10 mm Hg, N=179	16 weeks: >10 and ≤ 15 mm Hg, N=179	16 weeks: >15 and ≤ 20 mm Hg, N=179	16 weeks: >20 mm Hg, N=179	20 weeks: ≤ 10 mm Hg, N=166	20 weeks: >10 and ≤ 15 mm Hg, N=166	20 weeks: >15 and ≤ 20 mm Hg, N=166	20 weeks: >20 mm Hg, N=166
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	63.8	20.5	9.4	6.3	57.1	19.8	14.3	8.8	45.2	25.1	15.6	14.1	27.4	25.1	22.9	24.6	34.9	20.5	24.1	20.5

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=227	4 weeks: <135 mm Hg, N=227	4 weeks: <130 mm Hg, N=227	4 weeks: <120 mm Hg, N=227	8 weeks: <140 mm Hg, N=227	8 weeks: <135 mm Hg, N=227	8 weeks: <130 mm Hg, N=227	8 weeks: <120 mm Hg, N=227	12 weeks: <140 mm Hg, N=227	12 weeks: <135 mm Hg, N=227	12 weeks: <130 mm Hg, N=227	12 weeks: <120 mm Hg, N=227	16 weeks: <140 mm Hg, N=227	16 weeks: <135 mm Hg, N=227	16 weeks: <130 mm Hg, N=227	16 weeks: <120 mm Hg, N=227	20 weeks: <140 mm Hg, N=227	20 weeks: <135 mm Hg, N=227	20 weeks: <130 mm Hg, N=227	20 weeks: <120 mm Hg, N=227
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	52.0	37.9	23.4	9.7	67.0	57.7	43.6	18.1	80.6	70.0	56.8	28.6	87.7	79.7	70.9	43.6	91.6	85.9	78.9	50.7

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=224	4 weeks: >15 and ≤ 30 mm Hg, N=224	4 weeks: >30 and ≤ 45 mm Hg, N=224	4 weeks: >45 mm Hg, N=224	8 weeks: ≤ 15 mm Hg, N=217	8 weeks: >15 and ≤ 30 mm Hg, N=217	8 weeks: >30 and ≤ 45 mm Hg, N=217	8 weeks: >45 mm Hg, N=217	12 weeks: ≤ 15 mm Hg, N=199	12 weeks: >15 and ≤ 30 mm Hg, N=199	12 weeks: >30 and ≤ 45 mm Hg, N=199	12 weeks: >45 mm Hg, N=199	16 weeks: ≤ 15 mm Hg, N=179	16 weeks: >15 and ≤ 30 mm Hg, N=179	16 weeks: >30 and ≤ 45 mm Hg, N=179	16 weeks: >45 mm Hg, N=179	20 weeks: ≤ 15 mm Hg, N=166	20 weeks: >15 and ≤ 30 mm Hg, N=166	20 weeks: >30 and ≤ 45 mm Hg, N=166	20 weeks: >45 mm Hg, N=166
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	47.3	40.2	11.2	1.3	42.9	37.8	16.6	2.8	26.6	46.7	24.6	2.0	17.9	32.4	39.7	10.1	14.5	37.4	38.0	10.2

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=98	4 weeks: <85 mm Hg, N=98	4 weeks: <80 mm Hg, N=98	8 weeks: <90 mm Hg, N=100	8 weeks: <85 mm Hg, N=100	8 weeks: <80 mm Hg, N=100	12 weeks: <90 mm Hg, N=100	12 weeks: <85 mm Hg, N=100	12 weeks: <80 mm Hg, N=100	16 weeks: <90 mm Hg, N=100	16 weeks: <85 mm Hg, N=100	16 weeks: <80 mm Hg, N=100	20 weeks: <90 mm Hg, N=100	20 weeks: <85 mm Hg, N=100	20 weeks: <80 mm Hg, N=100
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	66.3	53.1	34.7	85.0	70.0	48.0	92.0	78.0	62.0	96.0	90.0	75.0	96.0	90.0	75.0

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=98	4 weeks: >10 and ≤ 15 mm Hg, N=98	4 weeks: >15 and ≤ 20 mm Hg, N=98	4 weeks: >20 mm Hg, N=98	8 weeks: ≤ 10 mm Hg, N=91	8 weeks: >10 and ≤ 15 mm Hg, N=91	8 weeks: >15 and ≤ 20 mm Hg, N=91	8 weeks: >20 mm Hg, N=91	12 weeks: ≤ 10 mm Hg, N=83	12 weeks: >10 and ≤15 mm Hg, N=83	12 weeks: >15 and ≤ 20 mm Hg, N=83	12 weeks: >20 mm Hg, N=83	16 weeks: ≤ 10 mm Hg, N=75	16 weeks: >10 and ≤ 15 mm Hg, N=75	16 weeks: >15 and ≤ 20 mm Hg, N=75	16 weeks: >20 mm Hg, N=75	20 weeks: ≤ 10 mm Hg, N=71	20 weeks: >10 and ≤ 15 mm Hg, N=71	20 weeks: >15 and ≤ 20 mm Hg, N=71	20 weeks: >20 mm Hg, N=71
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	65.3	16.3	8.2	10.2	52.8	18.7	14.3	14.3	41.0	20.5	14.5	24.1	30.7	25.3	16.0	28.0	31.0	12.7	26.8	29.6

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=98	4 weeks: <135 mm Hg, N=98	4 weeks: <130 mm Hg, N=98	4 weeks: <120 mm Hg, N=98	8 weeks: <140 mm Hg, N=100	8 weeks: <135 mm Hg, N=100	8 weeks: <130 mm Hg, N=100	8 weeks: <120 mm Hg, N=100	12 weeks: <140 mm Hg, N=100	12 weeks: <135 mm Hg, N=100	12 weeks: <130 mm Hg, N=100	12 weeks: <120 mm Hg, N=100	16 weeks: <140 mm Hg, N=100	16 weeks: <135 mm Hg, N=100	16 weeks: <130 mm Hg, N=100	16 weeks: <120 mm Hg, N=100	20 weeks: <140 mm Hg, N=100	20 weeks: <135 mm Hg, N=100	20 weeks: <130 mm Hg, N=100	20 weeks: <120 mm Hg, N=100
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	55.1	39.8	31.6	10.2	64.0	51.0	41.0	15.0	77.0	67.0	54.0	30.0	84.0	77.0	66.0	37.0	88.0	83.0	72.0	41.0

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=98	4 weeks: >15 and ≤ 30 mm Hg, N=98	4 weeks: >30 and ≤ 45 mm Hg, N=98	4 weeks: >45 mm Hg, N=98	8 weeks: ≤ 15 mm Hg, N=91	8 weeks: >15 and ≤ 30 mm Hg, N=91	8 weeks: >30 and ≤ 45 mm Hg, N=91	8 weeks: >45 mm Hg, N=91	12 weeks: ≤ 15 mm Hg, N=83	12 weeks: >15 and ≤ 30 mm Hg, N=83	12 weeks: >30 and ≤ 45 mm Hg, N=83	12 weeks: >45 mm Hg, N=83	16 weeks: ≤ 15 mm Hg, N=75	16 weeks: >15 and ≤ 30 mm Hg, N=75	16 weeks: >30 and ≤ 45 mm Hg, N=75	16 weeks: >45 mm Hg, N=75	20 weeks: ≤ 15 mm Hg, N=71	20 weeks: >15 and ≤ 30 mm Hg, N=71	20 weeks: >30 and ≤ 45 mm Hg, N=71	20 weeks: >45 mm Hg, N=71
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	50.0	37.8	7.1	5.1	42.9	44.0	9.9	3.3	31.3	36.1	25.3	7.2	22.7	36.0	34.7	6.7	23.9	33.8	33.8	8.5

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=497	4 weeks: <85 mm Hg, N=497	4 weeks: <80 mm Hg, N=497	8 weeks: <90 mm Hg, N=497	8 weeks: <85 mm Hg, N=500	8 weeks: <80 mm Hg, N=500	12 weeks: <90 mm Hg, N=500	12 weeks: <85 mm Hg, N=500	12 weeks: <80 mm Hg, N=500	16 weeks: <90 mm Hg, N=500	16 weeks: <85 mm Hg, N=500	16 weeks: <80 mm Hg, N=500	20 weeks: <90 mm Hg, N=500	20 weeks: <85 mm Hg, N=500	20 weeks: <80 mm Hg, N=500
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	63.2	46.3	26.0	77.2	59.4	38.8	86.6	69.8	48.4	93.2	80.4	60.4	94.6	83.8	67.6

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=495	4 weeks: >10 and ≤ 15 mm Hg, N=495	4 weeks: >15 and ≤ 20 mm Hg, N=495	4 weeks: >20 mm Hg, N=495	8 weeks: ≤ 10 mm Hg, N=468	8 weeks: >10 and ≤ 15 mm Hg, N=468	8 weeks: >15 and ≤ 20 mm Hg, N=468	8 weeks: >20 mm Hg, N=468	12 weeks: ≤ 10 mm Hg, N=436	12 weeks: >10 and ≤15 mm Hg, N=436	12 weeks: >15 and ≤ 20 mm Hg, N=436	12 weeks: >20 mm Hg, N=436	16 weeks: ≤ 10 mm Hg, N=400	16 weeks: >10 and ≤ 15 mm Hg, N=400	16 weeks: >15 and ≤ 20 mm Hg, N=400	16 weeks: >20 mm Hg, N=400	20 weeks: ≤ 10 mm Hg, N=379	20 weeks: >10 and ≤ 15 mm Hg, N=379	20 weeks: >15 and ≤ 20 mm Hg, N=379	20 weeks: >20 mm Hg, N=379
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	67.5	17.8	8.5	6.3	59.4	19.9	13.0	7.7	48.9	22.5	16.1	12.6	33.3	23.0	19.0	24.8	31.9	18.7	22.4	26.9

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=497	4 weeks: <135 mm Hg, N=497	4 weeks: <130 mm Hg, N=497	4 weeks: <120 mm Hg, N=497	8 weeks: <140 mm Hg, N=500	8 weeks: <135 mm Hg, N=500	8 weeks: <130 mm Hg, N=500	8 weeks: <120 mm Hg, N=500	12 weeks: <140 mm Hg, N=500	12 weeks: <135 mm Hg, N=500	12 weeks: <130 mm Hg, N=500	12 weeks: <120 mm Hg, N=500	16 weeks: <140 mm Hg, N=500	16 weeks: <135 mm Hg, N=500	16 weeks: <130 mm Hg, N=500	16 weeks: <120 mm Hg, N=500	20 weeks: <140 mm Hg, N=500	20 weeks: <135 mm Hg, N=500	20 weeks: <130 mm Hg, N=500	20 weeks: <120 mm Hg, N=500
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	51.3	37.2	23.3	7.9	63.2	49.2	37.0	13.8	76.6	61.6	49.2	23.2	85.8	75.6	63.6	34.6	90.2	82.6	72.2	43.0

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=495	4 weeks: >15 and ≤ 30 mm Hg, N=495	4 weeks: >30 and ≤ 45 mm Hg, N=495	4 weeks: >45 mm Hg, N=495	8 weeks: ≤ 15 mm Hg, N=468	8 weeks: >15 and ≤ 30 mm Hg, N=468	8 weeks: >30 and ≤ 45 mm Hg, N=468	8 weeks: >45 mm Hg, N=468	12 weeks: ≤ 15 mm Hg, N=436	12 weeks: >15 and ≤ 30 mm Hg, N=436	12 weeks: >30 and ≤ 45 mm Hg, N=436	12 weeks: >45 mm Hg, N=436	16 weeks: ≤ 15 mm Hg, N=400	16 weeks: >15 and ≤ 30 mm Hg, N=400	16 weeks: >30 and ≤ 45 mm Hg, N=400	16 weeks: >45 mm Hg, N=400	20 weeks: ≤ 15 mm Hg, N=379	20 weeks: >15 and ≤ 30 mm Hg, N=379	20 weeks: >30 and ≤ 45 mm Hg, N=379	20 weeks: >45 mm Hg, N=379
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	56.0	35.2	8.5	0.4	52.4	35.9	10.3	1.5	37.8	42.4	17.4	2.5	27.8	36.0	27.5	8.8	20.6	37.5	33.3	8.7

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. (NCT00791258)
Timeframe: Baseline to 12 weeks

Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Intervention	Percentage of participants (Number)
	24-hour mean systolic blood pressure <140 mmHg	24-hour mean systolic blood pressure <135 mmHg	24-hour mean systolic blood pressure <130 mmHg	24-hour mean systolic blood pressure <120 mmHg	24-hour mean diastolic blood pressure <90 mmHg	24-hour mean diastolic blood pressure <85 mmHg	24-hour mean diastolic blood pressure <80 mmHg	24-hour mean blood pressure <140/90 mmHg	24-hour mean blood pressure <135/95 mmHg	24-hour mean blood pressure <135/80 mmHg	24-hour mean blood pressure <130/80 mmHg	24-hour mean blood pressure <125/75 mmHg	24-hour mean blood pressure <120/80 mmHg	24-hour mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	95.6	90.4	79.9	47.2	98.7	96.1	84.7	94.3	89.1	80.3	73.4	52.4	45.9	27.5

Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Intervention	Percentage of participants (Number)
	24-hour mean systolic blood pressure <140 mmHg	24-hour mean systolic blood pressure <135 mmHg	24-hour mean systolic blood pressure <130 mmHg	24-hour mean systolic blood pressure <120 mmHg	24-hour mean diastolic blood pressure <90 mmHg	24-hour mean diastolic blood pressure <85 mmHg	24-hour mean diastolic blood pressure <80 mmHg	24-hour mean blood pressure <140/90 mmHg	24-hour mean blood pressure <135/95 mmHg	24-hour mean blood pressure <135/80 mmHg	24-hour mean blood pressure <130/80 mmHg	24-hour mean blood pressure <125/75 mmHg	24-hour mean blood pressure <120/80 mmHg	24-hour mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	99.5	97.5	94.5	70.4	100.0	97.5	93.0	99.5	96.0	92.5	90.5	75.4	70.4	55.3

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8AM - 4PM. (NCT00791258)
Timeframe: Baseline to 12 weeks

Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Intervention	Percentage of participants (Number)
	Daytime mean systolic blood pressure <140 mmHg	Daytime mean systolic blood pressure <135 mmHg	Daytime mean systolic blood pressure <130 mmHg	Daytime mean systolic blood pressure <120 mmHg	Daytime mean diastolic blood pressure <90 mmHg	Daytime mean diastolic blood pressure <85 mmHg	Daytime mean diastolic blood pressure <80 mmHg	Daytime mean blood pressure <140/90 mmHg	Daytime mean blood pressure <135/95 mmHg	Daytime mean blood pressure <135/80 mmHg	Daytime mean blood pressure <130/80 mmHg	Daytime mean blood pressure <125/75 mmHg	Daytime mean blood pressure <120/80 mmHg	Daytime mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	88.2	79.9	66.4	28.8	95.6	83.0	65.5	86.9	72.9	61.1	53.3	31.9	27.9	13.1

Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Intervention	Percentage of participants (Number)
	Daytime mean systolic blood pressure <140 mmHg	Daytime mean systolic blood pressure <135 mmHg	Daytime mean systolic blood pressure <130 mmHg	Daytime mean systolic blood pressure <120 mmHg	Daytime mean diastolic blood pressure <90 mmHg	Daytime mean diastolic blood pressure <85 mmHg	Daytime mean diastolic blood pressure <80 mmHg	Daytime mean blood pressure <140/90 mmHg	Daytime mean blood pressure <135/95 mmHg	Daytime mean blood pressure <135/80 mmHg	Daytime mean blood pressure <130/80 mmHg	Daytime mean blood pressure <125/75 mmHg	Daytime mean blood pressure <120/80 mmHg	Daytime mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	96.5	93.5	83.9	51.8	98.5	92.5	83.9	95.0	88.4	81.9	77.4	56.8	51.3	33.2

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10p.m. - 6 a.m. (NCT00791258)
Timeframe: Baseline to 12 weeks

Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Intervention	Percentage of participants (Number)
	Nighttime mean systolic blood pressure <140 mmHg	Nighttime mean systolic blood pressure <135 mmHg	Nighttime mean systolic blood pressure <130 mmHg	Nighttime mean systolic blood pressure <120 mmHg	Nighttime mean diastolic blood pressure <90 mmHg	Nighttime mean diastolic blood pressure <85 mmHg	Nighttime mean diastolic blood pressure <80 mmHg	Nighttime mean blood pressure <140/90 mmHg	Nighttime mean blood pressure <135/95 mmHg	Nighttime mean blood pressure <135/80 mmHg	Nighttime mean blood pressure <130/80 mmHg	Nighttime mean blood pressure <125/75 mmHg	Nighttime mean blood pressure <120/80 mmHg	Nighttime mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	97.8	94.3	92.6	74.7	99.6	98.3	94.8	97.4	93.4	90.8	89.1	77.7	74.2	62.0

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10 p.m. - 6 a.m. (NCT00791258)
Timeframe: Baseline to 20 weeks

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	88.5	75.2	62.0	33.6	94.7	83.2	61.1	86.7	55.8	49.6	29.2

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	93.8	87.6	79.7	47.8	98.2	89.4	77.0	92.9	74.3	69.9	43.4

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	73.5	59.0	47.9	18.8	86.3	72.7	48.7	68.4	40.2	34.2	16.2

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	89.7	83.8	69.2	41.0	91.5	85.5	69.2	85.5	64.1	59.8	36.8

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	92.8	82.5	78.3	51.2	94.6	86.8	71.7	88.6	67.5	65.1	48.2

Intervention	Percentage of Participants (Number)
	4 weeks: <140/90 mm Hg, N=975	4 weeks: <135/80 mm Hg, N=975	4 weeks: <130/80 mm Hg, N=975	4 weeks: <120/80 mm Hg, N=975	8 weeks: <140/90 mm Hg, N=929	8 weeks: <135/80 mm Hg, N=929	8 weeks: <130/80 mm Hg, N=929	8 weeks: <120/80 mm Hg, N=929	12 weeks: <140/90 mm Hg, N=865	12 weeks: <135/80 mm Hg, N=865	12 weeks: <130/80 mm Hg, N=865	12 weeks: <120/80 mm Hg, N=865	16 weeks: <140/90mm Hg, N=797	16 weeks: <135/80mm Hg, N=797	16 weeks: <130/80mm Hg, N=797	16 weeks: <120/80mm Hg, N=797	20 weeks: <140/90 mm Hg, N=745	20 weeks: <135/80 mm Hg, N=745	20 weeks: <130/80 mm Hg, N=745	20 weeks: <120/80 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	49.1	23.0	17.3	7.8	52.4	29.8	24.8	11.2	68.1	40.0	34.3	17.6	77.8	51.3	46.2	28.7	81.3	55.6	50.1	28.2

Intervention	Percentage of participants (Number)
	4 weeks: <90 mm Hg, N=975	4weeks: <85 mm Hg, N=975	4 weeks: <80 mm Hg, N=975	8 weeks: <90 mm Hg, N=929	8 weeks: <85 mm Hg, N=929	8 weeks: <80 mm Hg, N=929	12 weeks: <90 mm Hg, N=865	12 weeks: <85 mm Hg, N=865	12 weeks: <80 mm Hg, N=865	16 weeks: <90 mm Hg, N=797	16 weeks: <85 mm Hg, N=797	16 weeks: <80 mm Hg, N=797	20 weeks: <90 mm Hg, N=745	20 weeks: <85 mm Hg, N=745	20 weeks: <80 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	71.3	55.2	34.2	75.1	57.1	40.2	84.3	68.7	49.5	90.2	76.9	59.6	89.7	79.5	62.0

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=975	4 weeks: >10 and ≤ 15 mm Hg, N=975	4 weeks: >15 and ≤ 20 mm Hg, N=975	4 weeks: >20 mm Hg, N=975	8 weeks: ≤ 10 mm Hg, N=929	8 weeks: >10 and ≤ 15 mm Hg, N=929	8 weeks: >15 and ≤ 20 mm Hg, N=929	8 weeks: >20 mm Hg, N=929	12 weeks: ≤ 10 mm Hg, N=865	12 weeks: >10 and ≤ 15 mm Hg, N=865	12 weeks: >15 and ≤ 20 mm Hg, N=865	12 weeks: >20 mm Hg, N=865	16 weeks: ≤ 10 mm Hg, N=797	16 weeks: >10 and ≤ 15 mm Hg, N=797	16 weeks: >15 and ≤ 20 mm Hg, N=797	16 weeks: >20 mm Hg, N=797	20 weeks: ≤ 10 mm Hg, N=745	20 weeks: >10 and ≤ 15 mm Hg, N=745	20 weeks: >15 and ≤ 20 mm Hg, N=745	20 weeks: >20 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	61.3	21.0	10.5	7.2	54.7	20.7	14.1	10.6	43.8	24.1	15.8	16.3	30.4	22.8	21.5	25.4	31.4	19.9	22.6	26.2

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=975	4 weeks: <135 mm Hg, N=975	4 weeks: <130 mm Hg, N=975	4 weeks: <120 mm Hg, N=975	8 weeks: <140 mm Hg, N=929	8 weeks: <135 mm Hg, N=929	8 weeks: <130 mm Hg, N=929	8 weeks: <120 mm Hg, N=929	12 weeks: <140 mm Hg, N=865	12 weeks: <135 mm Hg, N=865	12 weeks: <130 mm Hg, N=865	12 weeks: <120 mm Hg, N=865	16 weeks: <140 mm Hg, N=797	16 weeks: <135 mm Hg, N=797	16 weeks: <130 mm Hg, N=797	16 weeks: <120 mm Hg, N=797	20 weeks: <140 mm Hg, N=745	20 weeks: <135 mm Hg, N=745	20 weeks: <130 mm Hg, N=745	20 weeks: <120 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	54.2	39.8	25.3	8.9	57.2	45.9	35.0	12.9	72.6	59.0	45.3	19.4	80.9	70.3	58.9	30.9	84.3	75.2	64.2	31.5

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=975	4 weeks: >15 and ≤ 30 mm Hg, N=975	4 weeks: >30 and ≤ 45 mm Hg, N=975	4 weeks: >45 mm Hg, N=975	8 weeks: ≤ 15 mm Hg, N=929	8 weeks: >15 and ≤ 30 mm Hg, N=929	8 weeks: >30 and ≤ 45 mm Hg, N=929	8 weeks: >45 mm Hg, N=929	12 weeks: ≤ 15 mm Hg, N=865	12 weeks: >15 and ≤ 30 mm Hg, N=865	12 weeks: >30 and ≤ 45 mm Hg, N=865	12 weeks: >45 mm Hg, N=865	16 weeks: ≤ 15 mm Hg, N=797	16 weeks: >15 and ≤ 30 mm Hg, N=797	16 weeks: >30 and ≤ 45 mm Hg, N=797	16 weeks: >45 mm Hg, N=797	20 weeks: ≤ 15 mm Hg, N=745	20 weeks: >15 and ≤ 30 mm Hg, N=745	20 weeks: >30 and ≤ 45 mm Hg, N=745	20 weeks: >45 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	51.4	36.6	10.5	1.5	45.8	37.7	14.3	2.3	30.5	43.1	22.4	3.9	23.2	35.9	32.0	8.9	20.4	36.2	34.0	9.4

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=454	4 weeks: <85 mm Hg, N=454	4 weeks: <80 mm Hg, N=454	8 weeks: <90 mm Hg, N=457	8 weeks: <85 mm Hg, N=457	8 weeks: <80 mm Hg, N=457	12 weeks: <90 mm Hg, N=457	12 weeks: <85 mm Hg, N=457	12 weeks: <80 mm Hg, N=457	16 weeks: <90 mm Hg, N=457	16 weeks: <85 mm Hg, N=457	16 weeks: <80 mm Hg, N=457	20 weeks: <90 mm Hg, N=457	20 weeks: <85 mm Hg, N=457	20 weeks: <80 mm Hg, N=457
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	69.6	53.5	31.9	82.1	66.1	43.5	90.4	76.6	56.5	94.8	83.2	65.9	95.4	86.2	72.0

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=453	4 weeks: >10 and ≤ 15 mm Hg, N=453	4 weeks: >15 and ≤ 20 mm Hg, N=453	4 weeks: >20 mm Hg, N=453	8 weeks: ≤ 10 mm Hg, N=431	8 weeks: >10 and ≤ 15 mm Hg, N=431	8 weeks: >15 and ≤ 20 mm Hg, N=431	8 weeks: >20 mm Hg, N=431	12 weeks: ≤ 10 mm Hg, N=402	12 weeks: >10 and ≤15 mm Hg, N=402	12 weeks: >15 and ≤ 20 mm Hg, N=402	12 weeks: >20 mm Hg, N=402	16 weeks: ≤ 10 mm Hg, N=371	16 weeks: >10 and ≤ 15 mm Hg, N=371	16 weeks: >15 and ≤ 20 mm Hg, N=371	16 weeks: >20 mm Hg, N=371	20 weeks: ≤ 10 mm Hg, N=356	20 weeks: >10 and ≤ 15 mm Hg, N=356	20 weeks: >15 and ≤ 20 mm Hg, N=356	20 weeks: >20 mm Hg, N=356
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	62.7	22.3	8.6	6.4	56.6	19.7	15.3	8.4	44.3	22.1	17.4	16.2	32.4	24.0	21.0	22.6	33.2	19.4	22.5	25.0

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=454	4 weeks: <135 mm Hg, N=454	4 weeks: <130 mm Hg, N=454	4 weeks: <120 mm Hg, N=454	8 weeks: <140 mm Hg, N=457	8 weeks: <135 mm Hg, N=457	8 weeks: <130 mm Hg, N=457	8 weeks: <120 mm Hg, N=457	12 weeks: <140 mm Hg, N=457	12 weeks: <135 mm Hg, N=457	12 weeks: <130 mm Hg, N=457	12 weeks: <120 mm Hg, N=457	16 weeks: <140 mm Hg, N=457	16 weeks: <135 mm Hg, N=457	16 weeks: <130 mm Hg, N=457	16 weeks: <120 mm Hg, N=457	20 weeks: <140 mm Hg, N=457	20 weeks: <135 mm Hg, N=457	20 weeks: <130 mm Hg, N=457	20 weeks: <120 mm Hg, N=457
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	56.4	41.4	27.1	7.9	67.6	54.3	40.9	16.2	81.4	67.2	54.1	27.6	88.8	80.3	67.0	39.0	91.5	85.6	74.8	47.1

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=453	4 weeks: >15 and ≤ 30 mm Hg, N=453	4 weeks: >30 and ≤ 45 mm Hg, N=453	4 weeks: >45 mm Hg, N=453	8 weeks: ≤ 15 mm Hg, N=431	8 weeks: >15 and ≤ 30 mm Hg, N=431	8 weeks: >30 and ≤ 45 mm Hg, N=431	8 weeks: >45 mm Hg, N=431	12 weeks: ≤ 15 mm Hg, N=402	12 weeks: >15 and ≤ 30 mm Hg, N=402	12 weeks: >30 and ≤ 45 mm Hg, N=402	12 weeks: >45 mm Hg, N=402	16 weeks: ≤ 15 mm Hg, N=371	16 weeks: >15 and ≤ 30 mm Hg, N=371	16 weeks: >30 and ≤ 45 mm Hg, N=371	16 weeks: >45 mm Hg, N=371	20 weeks: ≤ 15 mm Hg, N=356	20 weeks: >15 and ≤ 30 mm Hg, N=356	20 weeks: >30 and ≤ 45 mm Hg, N=356	20 weeks: >45 mm Hg, N=356
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	49.5	38.4	11.5	0.7	48.0	35.5	14.4	2.1	30.4	43.8	22.6	3.2	24.0	37.7	29.1	9.2	19.7	36.5	36.0	7.9

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=190	4 weeks: <85 mm Hg, N=190	4 weeks: <80 mm Hg, N=190	8 weeks: <90 mm Hg, N=190	8 weeks: <85 mm Hg, N=190	8 weeks: <80 mm Hg, N=190	12 weeks: <90 mm Hg, N=190	12 weeks: <85 mm Hg, N=190	12 weeks: <80 mm Hg, N=190	16 weeks: <90 mm Hg, N=190	16 weeks: <85 mm Hg, N=190	16 weeks: <80 mm Hg, N=190	20 weeks: <90 mm Hg, N=190	20 weeks: <85 mm Hg, N=190	20 weeks: <80 mm Hg, N=190
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	75.8	64.2	39.0	85.8	72.6	51.1	94.2	83.2	63.7	97.9	89.0	70.5	99.0	90.5	76.8

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=189	4 weeks: >10 and ≤ 15 mm Hg, N=189	4 weeks: >15 and ≤ 20 mm Hg, N=189	4 weeks: >20 mm Hg, N=189	8 weeks: ≤ 10 mm Hg, N=181	8 weeks: >10 and ≤ 15 mm Hg, N=181	8 weeks: >15 and ≤ 20 mm Hg, N=181	8 weeks: >20 mm Hg, N=181	12 weeks: ≤ 10 mm Hg, N=170	12 weeks: >10 and ≤15 mm Hg, N=170	12 weeks: >15 and ≤ 20 mm Hg, N=170	12 weeks: >20 mm Hg, N=170	16 weeks: ≤ 10 mm Hg, N=156	16 weeks: >10 and ≤ 15 mm Hg, N=156	16 weeks: >15 and ≤ 20 mm Hg, N=156	16 weeks: >20 mm Hg, N=156	20 weeks: ≤ 10 mm Hg, N=150	20 weeks: >10 and ≤ 15 mm Hg, N=150	20 weeks: >15 and ≤ 20 mm Hg, N=150	20 weeks: >20 mm Hg, N=150
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	67.7	16.9	11.6	3.7	60.8	20.4	14.9	3.9	41.2	32.4	12.9	13.5	32.7	26.9	21.8	18.6	37.3	18.0	26.0	18.7

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=190	4 weeks: <135 mm Hg, N=190	4 weeks: <130 mm Hg, N=190	4 weeks: <120 mm Hg, N=190	8 weeks: <140 mm Hg, N=190	8 weeks: <135 mm Hg, N=190	8 weeks: <130 mm Hg, N=190	8 weeks: <120 mm Hg, N=190	12 weeks: <140 mm Hg, N=190	12 weeks: <135 mm Hg, N=190	12 weeks: <130 mm Hg, N=190	12 weeks: <120 mm Hg, N=190	16 weeks: <140 mm Hg, N=190	16 weeks: <135 mm Hg, N=190	16 weeks: <130 mm Hg, N=190	16 weeks: <120 mm Hg, N=190	20 weeks: <140 mm Hg, N=190	20 weeks: <135 mm Hg, N=190	20 weeks: <130 mm Hg, N=190	20 weeks: <120 mm Hg, N=190
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	54.7	41.1	26.3	10.0	69.0	56.3	42.6	15.8	81.6	69.5	57.9	30.0	87.9	79.0	69.0	39.5	91.1	84.2	75.3	48.4

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=189	4 weeks: >15 and ≤ 30 mm Hg, N=189	4 weeks: >30 and ≤ 45 mm Hg, N=189	4 weeks: >45 mm Hg, N=189	8 weeks: ≤ 15 mm Hg, N=181	8 weeks: >15 and ≤ 30 mm Hg, N=181	8 weeks: >30 and ≤ 45 mm Hg, N=181	8 weeks: >45 mm Hg, N=181	12 weeks: ≤ 15 mm Hg, N=170	12 weeks: >15 and ≤ 30 mm Hg, N=170	12 weeks: >30 and ≤ 45 mm Hg, N=170	12 weeks: >45 mm Hg, N=170	16 weeks: ≤ 15 mm Hg, N=156	16 weeks: >15 and ≤ 30 mm Hg, N=156	16 weeks: >30 and ≤ 45 mm Hg, N=156	16 weeks: >45 mm Hg, N=156	20 weeks: ≤ 15 mm Hg, N=150	20 weeks: >15 and ≤ 30 mm Hg, N=150	20 weeks: >30 and ≤ 45 mm Hg, N=150	20 weeks: >45 mm Hg, N=150
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	56.1	36.0	7.9	0.0	54.1	34.3	11.6	0.0	35.3	38.2	22.9	3.5	28.2	40.4	26.3	5.1	26.0	40.0	26.7	7.3

Intervention	Percentage of participants (Number)
	12 weeks	20 weeks
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	71.3	84.8

Article	Year
Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors. Blood pressure, 2013, Volume: 22 Suppl 1 Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Diabetes Complication	2013
Adiponectin effects on the kidney. Best practice & research. Clinical endocrinology & metabolism, 2014, Volume: 28, Issue:1 Topics: Adiponectin; Albuminuria; Amlodipine; AMP-Activated Protein Kinases; Animals; Benzimidazoles; Benzoa	2014
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk]. Orvosi hetilap, 2008, Sep-28, Volume: 149, Issue:39 Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvast	2008
Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. Head and neck pathology, 2009, Volume: 3, Issue:2 Topics: Amlodipine; Antihypertensive Agents; Deglutition Disorders; Diabetes Mellitus, Type 2; Esophagectomy	2009
Angiotensin II type 1 receptor blockade: high hopes sent back to reality? Minerva cardioangiologica, 2009, Volume: 57, Issue:6 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih	2009
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. European heart journal, 2011, Volume: 32, Issue:12 Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure;	2011
[Large scale clinical trials in prevention of end-stage renal disease due to type 2 diabetes with angiotensin receptor antagonists]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:10 Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic;	2002
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. Presse medicale (Paris, France : 1983), 2002, Nov-09, Volume: 31, Issue:36 Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito	2002
Treatment of diabetic nephropathy with angiotensin II receptor antagonist. Clinical and experimental nephrology, 2003, Volume: 7, Issue:1 Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Creatinin	2003
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clinical therapeutics, 2003, Volume: 25, Issue:12 Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trial	2003
[Overview of cardiovascular risk factors]. Medicina clinica, 2006, Nov-25, Volume: 127, Issue:20 Topics: Age Factors; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; As	2006
[Type 2 diabetes and nephropathy--new studies, new treatment strategies?]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2002, Apr-10, Volume: 122, Issue:9 Topics: Amlodipine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calci	2002

Article	Year
Impact of simultaneous management of hypertension and hypercholesterolemia with ACE inhibitors and statins on cardiovascular outcomes in the Brisighella Heart Study: A 8-year follow-up. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2022, Volume: 32, Issue:9 Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Blood P	2022
Antihypertensive treatment improves glycemic control in patients with newly diagnosed type 2 diabetes mellitus: A prospective cohort study. Frontiers in endocrinology, 2022, Volume: 13 Topics: Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Glucose; Glycated Hemoglobin; Glycem	2022
Effects of Valsartan and Amlodipine Tablets Combined with α-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy. Alternative therapies in health and medicine, 2023, Volume: 29, Issue:5 Topics: Amlodipine; Antihypertensive Agents; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Nephropathies	2023
THE NITROSAMINE CONTAMINATION IN BETA BLOCKERS (BISOPROLOL/METOPROLOL), ACE INHIBITORS (LISINOPRIL/PERINDOPRIL), THIAZIDES DIURETICS (HCT), CALCIUM CHANNEL BLOCKERS (AMLODIPINE/FELODIPINE), SARTANS (CANDESARTAN) AND ТHE SUBSEQUENT SKIN CANCER DEVELOPMENT Georgian medical news, 2023, Issue:337 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih	2023
Treatment of calcium channel blocker-induced gingival overgrowth without modifying medication. BMJ case reports, 2021, Jan-11, Volume: 14, Issue:1 Topics: Aged; Amlodipine; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Gingival Overgrowth; Humans;	2021
More Than Meets the Eye: A Patient with Hand Swelling and Newly Diagnosed Diabetes Mellitus. The American journal of medicine, 2021, Volume: 134, Issue:11 Topics: Aged; Amlodipine; Anemia; Antihypertensive Agents; Blood Sedimentation; C-Reactive Protein; Diabetes	2021
Oxidative stress: link between hypertension and diabetes. The Korean journal of internal medicine, 2017, Volume: 32, Issue:3 Topics: Amlodipine; Diabetes Mellitus, Type 2; Humans; Hypertension; Oxidative Stress; Valsartan	2017
Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:7 Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cro	2018
[Influence of Therapy With Fixed Combination of Perindopril and Amlodipine on Parameters of Elasticity of Main Vessels and Microcirculation in Patients With Arterial Hypertension and Type 2 Diabetes Mellitus]. Kardiologiia, 2018, Issue:5 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Drug Combinati	2018
Effects of amlodipine and valsartan on glibenclamide-treated streptozotocin-induced diabetic rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 106 Topics: Amlodipine; Animals; Antihypertensive Agents; Biomarkers; Blood Glucose; Diabetes Mellitus, Experime	2018
Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril. Journal of hypertension, 2019, Volume: 37, Issue:3 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2;	2019
Utility of fixed-dose single tablet antihypertensive drug combinations in Cameroonians with type 2 diabetes and newly diagnosed hypertension. Journal of clinical hypertension (Greenwich, Conn.), 2019, Volume: 21, Issue:7 Topics: Africa South of the Sahara; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus,	2019
Concerns for the heart failure reduction in the NAGOYA HEART Study based on meta-regression from the evidence. Hypertension (Dallas, Tex. : 1979), 2013, Volume: 62, Issue:5 Topics: Amlodipine; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hypertens	2013
[Hypertension. Guidelines recommend fixed combinations]. MMW Fortschritte der Medizin, 2014, Apr-17, Volume: 156, Issue:7 Topics: Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Guideline Adheren	2014
[Effect of combination antihypertensive therapy on circadian blood pressure and metabolic parameters in patients with type 2 diabetes mellitus]. Kardiologiia, 2014, Volume: 54, Issue:11 Topics: Amlodipine; Antihypertensive Agents; Biological Availability; Blood Glucose; Blood Pressure; Blood P	2014
Effects of candesartan cilexetil and amlodipine orotate on receptor for advanced glycation end products expression in the aortic wall of Otsuka Long-Evans Tokushima Fatty (OETFF) type 2 diabetic rats. Archives of pharmacal research, 2016, Volume: 39, Issue:4 Topics: Amlodipine; Animals; Aorta; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Experimental; Dia	2016
Switching from a Free Association of Perindopril/Amlodipine to a Fixed-Dose Combination: Increased Antihypertensive Efficacy and Tolerability. Clinical drug investigation, 2016, Volume: 36, Issue:7 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cohort Studies; Diabetes Mellitus,	2016
Diabetes and hypertension: which is the best approach? Expert review of cardiovascular therapy, 2009, Volume: 7, Issue:3 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases;	2009
Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus. Journal of clinical hypertension (Greenwich, Conn.), 2009, Volume: 11, Issue:10 Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Black or African American; Blood Pr	2009
Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus. Cardiovascular therapeutics, 2011, Volume: 29, Issue:1 Topics: Adult; Aged; Amlodipine; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Typ	2011
Effects of antihypertensive drugs in the prevention of new-onset diabetes mellitus in patients with hypertension at high-risk of cardiovascular events in relation to aging. Journal of the American Geriatrics Society, 2010, Volume: 58, Issue:2 Topics: Age Distribution; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl C	2010
Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. Hypertension research : official journal of the Japanese Society of Hypertension, 2010, Volume: 33, Issue:6 Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles;	2010
The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors. Journal of human hypertension, 2011, Volume: 25, Issue:6 Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Comorbidity; Diabetes	2011
Scintigraphic diagnosis of Erdheim-Chester disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-01, Volume: 29, Issue:16 Topics: Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Erdheim-Che	2011
[A powerful duo: antihypertensives aliskiren and amlodipine in one tablet. Combination tablet for hypertensive patients with diabetes and overweight]. MMW Fortschritte der Medizin, 2011, May-12, Volume: 153, Issue:19 Topics: Amides; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship,	2011
Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:6 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Di	2012
Targeting albuminuria in arterial hypertension and diabetes: how is it best achieved and what is its clinical relevance? Journal of hypertension, 2013, Volume: 31, Issue:1 Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood P	2013
Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease. Annals of internal medicine, 2003, Apr-01, Volume: 138, Issue:7 Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp	2003
[Heart rate variability in patients with hypertension and type 2 diabetes treated with long acting calcium antagonists]. Kardiologiia, 2003, Volume: 43, Issue:5 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Calcium Channel Bl	2003
The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clinical therapeutics, 2003, Volume: 25, Issue:7 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Cost-Benefit Analysis; Diabete	2003
[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension]. Deutsche medizinische Wochenschrift (1946), 2004, Jan-02, Volume: 129, Issue:1-2 Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Computer Simulation; Creatinine; Diabetes M	2004
[Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk]. MMW Fortschritte der Medizin, 2004, Jul-08, Volume: 146, Issue:27-28 Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Diabetes	2004
[VALUE study underscores the significance of reaching aimed blood pressure values for minimizing cardiovascular risks]. Praxis, 2004, Oct-13, Volume: 93, Issue:42 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular	2004
[VALUE study underscores the importance of reaching goal blood pressure values for minimization of cardiovascular risks]. Praxis, 2004, Oct-27, Volume: 93, Issue:44 Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel	2004
Effect of amlodipine on insulin resistance & tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patients. The Indian journal of medical research, 2004, Volume: 120, Issue:5 Topics: Adolescent; Adult; Aged; Amlodipine; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Female; Ho	2004
[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]. Praxis, 2006, Mar-15, Volume: 95, Issue:11 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Ca	2006
Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. Archives of internal medicine, 2006, Apr-10, Volume: 166, Issue:7 Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Antihypertensive Agents; Black or African American;	2006
[The most recent study into blood pressure lowering by amlodipine: the beginning of the end for the beta-blockers]. Nederlands tijdschrift voor geneeskunde, 2006, Apr-22, Volume: 150, Issue:16 Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Dis	2006
Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. Journal of human hypertension, 2007, Volume: 21, Issue:5 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Databases, Factual; Diabetes Mellitus; Diabetes Me	2007
Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. American journal of hypertension, 2007, Volume: 20, Issue:4 Topics: Adipocytes; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates;	2007
[Hypertension therapy for type 2 diabetics]. MMW Fortschritte der Medizin, 2007, Jun-07, Volume: 149, Issue:23 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih	2007
Chronic kidney disease--a disease domain complex. Geriatrics, 2008, Volume: 63, Issue:3 Topics: Aged; Alendronate; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Asp	2008
Albuminuria in diabetes mellitus: relation to ambulatory versus office blood pressure and effects of cilazapril. American journal of hypertension, 1996, Volume: 9, Issue:12 Pt 1 Topics: Adolescent; Adult; Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pr	1996
Role of intrarenal angiotensin-converting enzyme in nephropathy of type II diabetic rats. Hypertension research : official journal of the Japanese Society of Hypertension, 2002, Volume: 25, Issue:2 Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressu	2002

amlodipine and Diabetes Mellitus, Type 2

Research Excerpts

Research

Studies (164)

Authors

Clinical Trials (23)

Trial Overview

Trial Outcomes

Diastolic Blood Pressure

Endothelial Function

Systolic Blood Pressure

Vascular Stiffness

Vascular Stiffness by Augmentation Index

The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks

The Percentage of Subjects Achieving Seated Diastolic BP Goal (<90 mmHg for Non-diabetics or < 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks

Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values

Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values

Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks

Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

The Percentage of Subjects Who Achieve BP Goal (<140/90 mmHg for Non-diabetics or <130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks

Reviews

Trials

Other Studies